Hugging Face's logo

Datasets:
FrancophonIA
/
European_Vaccination_Information_Portal

Tasks:
Translation
Languages:
English
Bulgarian
Czech
Dataset card Files Community
European_Vaccination_Information_Portal / data /en-mt.tmx
de-francophones's picture
de-francophones
Upload 23 files
66ba51a verified
raw
history blame contribute delete
218 kB
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<tmx version="1.4">
<header adminlang="en" creationdate="20200424T153633Z" creationtool="mALIGNa" creationtoolversion="2" datatype="plaintext" o-tmf="al" segtype="block" srclang="mt">
<prop type="distributor">ELRC project</prop>
<prop type="description">Acquisition of bilingual data (from multilingual websites), normalization, cleaning, deduplication and identification of parallel documents have been done by ILSP-FC tool. Maligna aligner was used for alignment of segments. Merging/filtering of segment pairs has also been applied.</prop>
<prop type="l1">mt</prop>
<prop type="l2">en</prop>
<prop type="lengthInTUs">472</prop>
<prop type="# of words in l1">7112</prop>
<prop type="# of words in l2">7562</prop>
<prop type="# of unique words in l1">1396</prop>
<prop type="# of unique words in l2">1577</prop>
</header>
<body>
<tu tuid="1">
<prop type="lengthRatio">0.6470588235294118</prop>
<tuv xml:lang="en">
<seg>its purity;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-purità tiegħu;</seg>
</tuv>
</tu>
<tu tuid="2">
<prop type="lengthRatio">1.0333333333333334</prop>
<tuv xml:lang="en">
<seg>Are there serious side effects?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hemm effetti sekondarji serji?</seg>
</tuv>
</tu>
<tu tuid="3">
<prop type="lengthRatio">1.2105263157894737</prop>
<tuv xml:lang="en">
<seg>Thousands of volunteers</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Eluf ta' voluntiera</seg>
</tuv>
</tu>
<tu tuid="4">
<prop type="lengthRatio">0.8395061728395061</prop>
<tuv xml:lang="en">
<seg>its ingredients, including its inactive ingredients or ‘excipients';</seg>
</tuv>
<tuv xml:lang="mt">
<seg>l-ingredjenti tiegħu, inkluż l-ingredjenti mhux attivi tiegħu jew l-"eċċipjenti";</seg>
</tuv>
</tu>
<tu tuid="5">
<prop type="lengthRatio">1.4285714285714286</prop>
<tuv xml:lang="en">
<seg>Does the vaccine seem to work?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin huwa sikur?</seg>
</tuv>
</tu>
<tu tuid="6">
<prop type="lengthRatio">1.140625</prop>
<tuv xml:lang="en">
<seg>How are the immune systems of the participants responding to the vaccine?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-sistemi immuni tal-parteċipanti kif jirrispondu għall-vaċċin?</seg>
</tuv>
</tu>
<tu tuid="7">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>This involves tests in the laboratory and in animals.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jinvolvi testijiet fil-laboratorju u fl-annimali.</seg>
</tuv>
</tu>
<tu tuid="8">
<prop type="lengthRatio">0.9368421052631579</prop>
<tuv xml:lang="en">
<seg>These include the European Medicines Agency and other regulators in the EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jinkludu l-Aġenzija Ewropea għall-Mediċini u regolaturi oħrajn fil-pajjiżi tal-UE/taż-ŻEE.</seg>
</tuv>
</tu>
<tu tuid="9">
<prop type="lengthRatio">0.8372093023255814</prop>
<tuv xml:lang="en">
<seg>At the end of the testing programme, the vaccine developer submits the results to the medicines regulatory authorities in Europe as part of a ‘marketing authorisation' application.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fl-aħħar tal-programm ta' ttestjar, l-iżviluppatur tal-vaċċin jissottometti r-riżultati lill-awtoritajiet regolatorji tal-mediċini fl-Ewropa bħala parti minn applikazzjoni ta' "awtorizzazzjoni għat-tqegħid fis-suq".</seg>
</tuv>
</tu>
<tu tuid="10">
<prop type="lengthRatio">0.9325842696629213</prop>
<tuv xml:lang="en">
<seg>This is followed by a clinical testing programme in humans, which can take around ten years from initial concept to authorisation and must adhere to strict standards.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jiġi segwit minn programm ta' ttestjar kliniku fil-bnedmin, li jista' jieħu sa għaxar snin mill-kunċett inizjali sal-awtorizzazzjoni u għandu jaderixxi ma' standards stretti.</seg>
</tuv>
</tu>
<tu tuid="11">
<prop type="lengthRatio">0.8085106382978723</prop>
<tuv xml:lang="en">
<seg>What are the most common side effects?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Liema huma l-effetti sekondarji l-aktar komuni?</seg>
</tuv>
</tu>
<tu tuid="12">
<prop type="lengthRatio">0.8224852071005917</prop>
<tuv xml:lang="en">
<seg>Medicines regulatory authorities can carry out inspections to make sure that the information the vaccine developer provides is trustworthy.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-awtoritajiet regolatorji tal-mediċini jistgħu jagħmlu spezzjonijiet biex jiżguraw li l-informazzjoni li jipprovdi l-iżviluppatur tal-vaċċin hija ta' min joqgħod fuqha.</seg>
</tuv>
</tu>
<tu tuid="13">
<prop type="lengthRatio">0.9090909090909091</prop>
<tuv xml:lang="en">
<seg>The companies are required to conduct stringent testing, for which the acceptance criteria are pre-defined by the authorities, on each batch of vaccine released onto the EU market.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kumpaniji huma meħtieġa jwettqu ttestjar strinġenti, li għalih, il-kriterji tal-aċċettazzjoni tiegħu jiġu definiti minn qabel mill-awtoritajiet, fuq kull lott ta' vaċċini rilaxxat fis-suq tal-UE.</seg>
</tuv>
</tu>
<tu tuid="14">
<prop type="lengthRatio">0.963855421686747</prop>
<tuv xml:lang="en">
<seg>This programme has to follow the procedures and protocols set by the regulators:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan il-programm għandu jsegwi l-proċeduri u l-protokolli stabbiliti mir-regolaturi:</seg>
</tuv>
</tu>
<tu tuid="15">
<prop type="lengthRatio">1.0454545454545454</prop>
<tuv xml:lang="en">
<seg>how it is manufactured.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kif jiġi manifatturat.</seg>
</tuv>
</tu>
<tu tuid="16">
<prop type="lengthRatio">0.85</prop>
<tuv xml:lang="en">
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer and then scientific evaluation by regulatory authorities.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Qabel ma vaċċin ikun jista' jiġi approvat fl-UE, irid jgħaddi minn ittestjar rigoruż mill-iżviluppatur tiegħu, u mbagħad minn evalwazzjoni xjentifika mill-awtoritajiet regolatorji.</seg>
</tuv>
</tu>
<tu tuid="17">
<prop type="lengthRatio">1.4090909090909092</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Benefiċċji tat-tlaqqim</seg>
</tuv>
</tu>
<tu tuid="18">
<prop type="lengthRatio">0.8</prop>
<tuv xml:lang="en">
<seg>Testing includes checking the vaccine's quality:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ittestjar jinkludi li tiġi ċċekkjata l-kwalità tal-vaċċin:</seg>
</tuv>
</tu>
<tu tuid="19">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>The vaccine developer tests the vaccine in three phases of clinical trials, with larger numbers of people in each phase.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iżviluppatur tal-vaċċin jittestja l-vaċċin fi tliet fażijiet ta' provi kliniċi, b'numri akbar ta' persuni f'kull fażi.</seg>
</tuv>
</tu>
<tu tuid="20">
<prop type="lengthRatio">0.8857142857142857</prop>
<tuv xml:lang="en">
<seg>The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine's benefits are greater than its risks .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-regolaturi jistgħu japprovaw il-vaċċin biss jekk l-evalwazzjoni xjentifika tar-riżultati tat-testijiet tiegħu turi li l- benefiċċji tal-vaċċin huma akbar mir-riskji tiegħu.</seg>
</tuv>
</tu>
<tu tuid="21">
<prop type="lengthRatio">0.5348837209302325</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Approvazzjoni tal-vaċċini fl-Unjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="22">
<prop type="lengthRatio">0.8333333333333334</prop>
<tuv xml:lang="en">
<seg>Then the vaccine developer tests the vaccine's effects.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Imbagħad l-iżviluppatur tal-vaċċin jittestja l-effetti tal-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="23">
<prop type="lengthRatio">1.25</prop>
<tuv xml:lang="en">
<seg>What is the optimal dose?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi l-aħjar doża?</seg>
</tuv>
</tu>
<tu tuid="24">
<prop type="lengthRatio">0.9570552147239264</prop>
<tuv xml:lang="en">
<seg>They can also run tests to make sure that the batches of vaccines released onto the market are of the expected quality and have been manufactured correctly.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jistgħu wkoll jagħmlu testijiet biex jiżguraw li l-lottijiet tal-vaċċini rilaxxati fis-suq ikunu tal-kwalità mistennija u jkunu ġew manifatturati kif suppost.</seg>
</tuv>
</tu>
<tu tuid="25">
<prop type="lengthRatio">0.6451612903225806</prop>
<tuv xml:lang="en">
<seg>Is the vaccine safe?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin jidher li qed jaħdem?</seg>
</tuv>
</tu>
<tu tuid="26">
<prop type="lengthRatio">0.9863013698630136</prop>
<tuv xml:lang="en">
<seg>Vaccination is the only way to ensure direct protection against tetanus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim huwa l-uniku mod li jiżgura protezzjoni diretta kontra t-tetnu.</seg>
</tuv>
</tu>
<tu tuid="27">
<prop type="lengthRatio">0.980544747081712</prop>
<tuv xml:lang="en">
<seg>For example, to ensure community immunity against measles, public health authorities recommend that 95% of the population are vaccinated with two doses of the vaccine against measles (the MMR vaccine, which protects against measles, mumps and rubella).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, biex jiżguraw l-immunità komunitarja kontra l-ħosba, l-awtoritajiet tas-saħħa pubblika jirrakkomandaw li 95 % tal-popolazzjoni jitlaqqmu b'żewġ dożi tal-vaċċin kontra l-ħosba (il-vaċċin MMR, li jipproteġi kontra l-ħosba, il-gattone u r-rubella).</seg>
</tuv>
</tu>
<tu tuid="28">
<prop type="lengthRatio">1.0292887029288702</prop>
<tuv xml:lang="en">
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases, reducing the risk of diseases spreading among family members, school mates or colleagues, friends, neighbours and other people in the community.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-persuni mlaqqma u lill-persuni ta' madwarhom li huma vulnerabbli għall-mard, inaqqas ir-riskju li l-mard jinfirex fost il-membri tal-familja, ħbieb tal-iskola, kollegi, ħbieb, ġirien u persuni oħrajn fil-komunità.</seg>
</tuv>
</tu>
<tu tuid="29">
<prop type="lengthRatio">0.8351648351648352</prop>
<tuv xml:lang="en">
<seg>This is known as 'community immunity' (also referred to as 'herd immunity').</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din hija magħrufa bħala "immunità komunitarja" (li tissejjaħ ukoll "immunità bħala grupp").</seg>
</tuv>
</tu>
<tu tuid="30">
<prop type="lengthRatio">0.8637770897832817</prop>
<tuv xml:lang="en">
<seg>Furthermore, immunisation programmes help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Barra minn hekk, il-programmi tal-immunizzazzjoni jgħinu biex inaqqsu l-piżijiet soċjali, psikoloġiċi u finanzjarji tal-mard fuq in-nies u l-gvernijiet, inaqqsu l-pressjonijiet fuq is-sistemi tal-kura tas-saħħa u tal-kura soċjali u jippermettu lin-nies iwettqu attivitajiet produttivi li jinkludu l-edukazzjoni u l-impjieg.</seg>
</tuv>
</tu>
<tu tuid="31">
<prop type="lengthRatio">0.9504950495049505</prop>
<tuv xml:lang="en">
<seg>Community immunity occurs when enough people in a population are immune to an infectious disease</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-immunità komunitarja sseħħ meta biżżejjed persuni f'popolazzjoni jkunu immuni għal marda infettiva.</seg>
</tuv>
</tu>
<tu tuid="32">
<prop type="lengthRatio">0.8586956521739131</prop>
<tuv xml:lang="en">
<seg>However, people cannot rely on community immunity for some infectious diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, in-nies ma jistgħux jiddependu fuq l-immunità komunitarja għal xi mard infettiv.</seg>
</tuv>
</tu>
<tu tuid="33">
<prop type="lengthRatio">0.883495145631068</prop>
<tuv xml:lang="en">
<seg>For example, tetanus can be encountered due to common injuries, including dog or cat bites.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, it-tetnu jista' jittieħed minħabba korrimenti komuni, inkluż gdim tal-klieb jew tal-qtates.</seg>
</tuv>
</tu>
<tu tuid="34">
<prop type="lengthRatio">1.0512820512820513</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for the community</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-benefiċċji tat-tilqim għall-komunità</seg>
</tuv>
</tu>
<tu tuid="35">
<prop type="lengthRatio">1.054054054054054</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for individuals</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Benefiċċji tat-tilqim għall-individwi</seg>
</tuv>
</tu>
<tu tuid="36">
<prop type="lengthRatio">0.8988095238095238</prop>
<tuv xml:lang="en">
<seg>These include babies, children, the elderly, people with weak immune systems, cancer patients, and people who cannot be vaccinated for medical reasons.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jinkludu t-trabi, it-tfal, l-anzjani, il-persuni b'sistemi immunitarja dgħajfa, pazjenti bil-kanċer, u persuni li ma jistgħux jitlaqqmu minħabba raġunijiet mediċi.</seg>
</tuv>
</tu>
<tu tuid="37">
<prop type="lengthRatio">0.75</prop>
<tuv xml:lang="en">
<seg>In this way, vaccines indirectly protect others who are vulnerable to disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>B'dan il-mod, il-vaċċini b'mod indirett jipproteġu lill-persuni l-oħra li jkunu vulnerabbli għall-marda.</seg>
</tuv>
</tu>
<tu tuid="38">
<prop type="lengthRatio">0.8181818181818182</prop>
<tuv xml:lang="en">
<seg>red rash;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>raxx aħmar;</seg>
</tuv>
</tu>
<tu tuid="39">
<prop type="lengthRatio">1.0298507462686568</prop>
<tuv xml:lang="en">
<seg>Up to 50% of people infected with rubella do not experience symptoms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sa 50 % tal-persuni infettati bir-rubella ma jesperjenzawx sintomi.</seg>
</tuv>
</tu>
<tu tuid="40">
<prop type="lengthRatio">0.952</prop>
<tuv xml:lang="en">
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR (il-ħosba, il-gattone u r-rubella) huwa vaċċin ikkombinat li jipproteġi kontra l-ħosba, il-gattone u r-rubella.</seg>
</tuv>
</tu>
<tu tuid="41">
<prop type="lengthRatio">0.8363636363636363</prop>
<tuv xml:lang="en">
<seg>Rubella (German measles) is a viral infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-Rubella (il-ħosba Ġermaniża) hija infezzjoni virali.</seg>
</tuv>
</tu>
<tu tuid="42">
<prop type="lengthRatio">1.0952380952380953</prop>
<tuv xml:lang="en">
<seg>pain and inflammation of the joints in adults.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>uġigħ u infjammazzjoni tal-ġogi fl-adulti.</seg>
</tuv>
</tu>
<tu tuid="43">
<prop type="lengthRatio">1.064516129032258</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of rubella?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi tar-rubella?</seg>
</tuv>
</tu>
<tu tuid="44">
<prop type="lengthRatio">0.6341463414634146</prop>
<tuv xml:lang="en">
<seg>Who is at risk of rubella?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min qiegħed f'riskju li taqbdu r-rubella?</seg>
</tuv>
</tu>
<tu tuid="45">
<prop type="lengthRatio">0.911504424778761</prop>
<tuv xml:lang="en">
<seg>The rubella virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-virus tar-rubella jinfirex minn taqtiriet fl-arja li jiġu prodotti meta l-persuna infettata tisgħol u tagħtas.</seg>
</tuv>
</tu>
<tu tuid="46">
<prop type="lengthRatio">0.9411764705882353</prop>
<tuv xml:lang="en">
<seg>What is rubella?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi r-rubella?</seg>
</tuv>
</tu>
<tu tuid="47">
<prop type="lengthRatio">0.9315068493150684</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine is safe and effective and has very few side effects.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR huwa sikur u effikaċi u ma tantx għandu effetti sekondarji.</seg>
</tuv>
</tu>
<tu tuid="48">
<prop type="lengthRatio">0.9856459330143541</prop>
<tuv xml:lang="en">
<seg>The consequences for unvaccinated pregnant women that get rubella are particularly severe, due to the likelihood that contracting the disease during pregnancy can lead to miscarriage or CRS in their babies.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-konsegwenzi għan-nisa tqal li mhumiex imlaqqma li taqbadhom ir-rubella huma partikolarment severi, probabbli minħabba l-fatt li l-marda waqt it-tqala tista' twassal għal korriment jew CRS fit-trabi tagħhom.</seg>
</tuv>
</tu>
<tu tuid="49">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>The only protection against rubella is vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-unika protezzjoni kontra r-rubella hija t-tilqim.</seg>
</tuv>
</tu>
<tu tuid="50">
<prop type="lengthRatio">0.7967032967032966</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7-14 days after vaccination, which disappears within 1-3 days.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi reċipjenti tal-vaċċin jiżviluppaw raxx ħafif mhux infettiv li jixbah lill-ħosba, tipikament bejn sebat ijiem u 14-il jum wara t-tilqima, li jisparixxi bejn jum u tlett ijiem wara.</seg>
</tuv>
</tu>
<tu tuid="51">
<prop type="lengthRatio">0.9444444444444444</prop>
<tuv xml:lang="en">
<seg>However, if a woman gets rubella during the first three months of pregnancy, it is very likely to result in miscarriage or a baby born with congenital anomalies known as congenital rubella syndrome (CRS).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, jekk mara taqbadha r-rubella matul l-ewwel tliet xhur tat-tqala, x'aktarx li tirriżulta f'korriment jew f'tarbija li titwieled b'disturbi konġenitali magħrufa bħala sindrome tar-rubella konġenitali (CRS).</seg>
</tuv>
</tu>
<tu tuid="52">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>swollen lymph glands around the ears and the back of the head;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>għoqiedi limfatiċi minfuħa madwar il-widnejn u f'wara tar-ras;</seg>
</tuv>
</tu>
<tu tuid="53">
<prop type="lengthRatio">0.8940397350993378</prop>
<tuv xml:lang="en">
<seg>Women who plan to become pregnant should check their vaccination status, as they cannot be vaccinated against rubella during pregnancy.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>In-nisa li beħsiebhom joħorġu tqal għandhom jivverifikaw l-istatus ta' tilqim tagħhom, peress li ma jistgħux jitlaqqmu kontra r-rubella matul it-tqala.</seg>
</tuv>
</tu>
<tu tuid="54">
<prop type="lengthRatio">0.9122807017543859</prop>
<tuv xml:lang="en">
<seg>In healthy individuals it is usually a mild disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'individwi b'saħħithom din normalment tkun marda ħafifa.</seg>
</tuv>
</tu>
<tu tuid="55">
<prop type="lengthRatio">1.0521739130434782</prop>
<tuv xml:lang="en">
<seg>Anyone who has not had the disease or who has not been vaccinated with the MMR vaccine is at risk of contracting rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull min għadha ma qabditux il-marda jew min ma kienx imlaqqam bil-vaċċin MMR qiegħed f'riskju li taqbdu r-rubella.</seg>
</tuv>
</tu>
<tu tuid="56">
<prop type="lengthRatio">1.4074074074074074</prop>
<tuv xml:lang="en">
<seg>What are the complications of rubella?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi kkurata r-rubella?</seg>
</tuv>
</tu>
<tu tuid="57">
<prop type="lengthRatio">0.8409090909090909</prop>
<tuv xml:lang="en">
<seg>CRS can lead to deafness, cataracts and learning disabilities in the baby.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-CRS tista' twassal għal truxija, katarretti u diżabilitajiet fit-tagħlim fit-tarbija.</seg>
</tuv>
</tu>
<tu tuid="58">
<prop type="lengthRatio">1.0277777777777777</prop>
<tuv xml:lang="en">
<seg>When symptoms do occur, they include:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta s-sintomi jidhru, dawn jikludu:</seg>
</tuv>
</tu>
<tu tuid="59">
<prop type="lengthRatio">0.9672131147540983</prop>
<tuv xml:lang="en">
<seg>Two doses of the vaccine are needed for maximum protection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-protezzjoni massima huma meħtieġa żewġ dożi tal-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="60">
<prop type="lengthRatio">0.6216216216216216</prop>
<tuv xml:lang="en">
<seg>How is rubella treated?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta r-rubella?</seg>
</tuv>
</tu>
<tu tuid="61">
<prop type="lengthRatio">0.8297872340425532</prop>
<tuv xml:lang="en">
<seg>European Vaccination Information Portal</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Portal Ewropew ta 'Informazzjoni dwar it-Tilqim</seg>
</tuv>
</tu>
<tu tuid="62">
<prop type="lengthRatio">0.9375</prop>
<tuv xml:lang="en">
<seg>In Europe, influenza occurs...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fl-Ewropa, l-influwenza sseħħ...</seg>
</tuv>
</tu>
<tu tuid="63">
<prop type="lengthRatio">0.9696969696969697</prop>
<tuv xml:lang="en">
<seg>Influenza (flu) is a contagious respiratory illness caused by infection with an influenza virus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-influwenza hija marda respiratorja li tittieħed ikkawżata minn infezzjoni b'virus tal-influwenza.</seg>
</tuv>
</tu>
<tu tuid="64">
<prop type="lengthRatio">1.0252100840336134</prop>
<tuv xml:lang="en">
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull virus u batterju joħloq reazzjoni unika fis-sistema immunitarja li tinvolvi sett speċifiku ta' ċelloli fid-demm...</seg>
</tuv>
</tu>
<tu tuid="65">
<prop type="lengthRatio">1.0333333333333334</prop>
<tuv xml:lang="en">
<seg>Vaccination protects individuals against diseases that could have serious consequences for...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-individwi kontra mard li jista' jkollu konsegwenzi serji għal...</seg>
</tuv>
</tu>
<tu tuid="66">
<prop type="lengthRatio">2.0727272727272728</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-rubella (il-ħosba Ġermaniża) hija infezzjoni virali.</seg>
</tuv>
</tu>
<tu tuid="67">
<prop type="lengthRatio">1.10752688172043</prop>
<tuv xml:lang="en">
<seg>Vaccination protects the vaccinated persons and those around them who are vulnerable to the diseases...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-persuni mlaqqma u lill-persuni ta' madwarhom li huma vulnerabbli...</seg>
</tuv>
</tu>
<tu tuid="68">
<prop type="lengthRatio">1.2142857142857142</prop>
<tuv xml:lang="en">
<seg>When to vaccinate</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tagħbija aktar</seg>
</tuv>
</tu>
<tu tuid="69">
<prop type="lengthRatio">0.8615384615384616</prop>
<tuv xml:lang="en">
<seg>Vaccines protect people during different stages of life.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini jipproteġu lin-nies matul stadji differenti tal-ħajja.</seg>
</tuv>
</tu>
<tu tuid="70">
<prop type="lengthRatio">0.6818181818181818</prop>
<tuv xml:lang="en">
<seg>Vaccines are recommended for different age...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini huma rakkomandati għal gruppi ta' etajiet differenti...</seg>
</tuv>
</tu>
<tu tuid="71">
<prop type="lengthRatio">0.9333333333333333</prop>
<tuv xml:lang="en">
<seg>Before a vaccine can be approved in the EU, it has to undergo rigorous testing by its developer...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Qabel ma vaċċin ikun jista' jiġi approvat fl-UE, irid jgħaddi minn ittestjar rigoruż mill-iżviluppatur...</seg>
</tuv>
</tu>
<tu tuid="72">
<prop type="lengthRatio">1.5</prop>
<tuv xml:lang="en">
<seg>Trusted sources</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aqra iktar</seg>
</tuv>
</tu>
<tu tuid="73">
<prop type="lengthRatio">0.994413407821229</prop>
<tuv xml:lang="en">
<seg>It also provides an overview of the mechanisms in place in the European Union (EU) to ensure that available vaccines conform to the highest standards of safety and effectiveness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jipprovdi wkoll ħarsa ġenerali lejn il-mekkaniżmi implimentati fl-Unjoni Ewropea (UE) biex jiġi żgurat li l-vaċċini jikkonformaw mal-ogħla standards ta' sigurtà u effettività.</seg>
</tuv>
</tu>
<tu tuid="74">
<prop type="lengthRatio">1.1505376344086022</prop>
<tuv xml:lang="en">
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis hija marda batterika infettiva ħafna li tinvolvi l-pulmun u l-passaġġi tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="75">
<prop type="lengthRatio">0.9666666666666667</prop>
<tuv xml:lang="en">
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iskop ewlieni ta' dan is-sit web huwa li jipprovdi evidenza preċiża, oġġettiva u aġġornata dwar il-vaċċini u t-tilqim.</seg>
</tuv>
</tu>
<tu tuid="76">
<prop type="lengthRatio">2.2280701754385963</prop>
<tuv xml:lang="en">
<seg>The main purpose of this website is to provide accurate, objective, up-to-date evidence on vaccines and vaccination in general.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'individwi b'saħħithom din normalment tkun marda ħafifa.</seg>
</tuv>
</tu>
<tu tuid="77">
<prop type="lengthRatio">1.3411764705882352</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Kummissjoni hija maqsuma f'dipartimenti li jiżviluppaw politiki f'oqsma speċifiċi.</seg>
</tuv>
</tu>
<tu tuid="78">
<prop type="lengthRatio">0.9767441860465116</prop>
<tuv xml:lang="en">
<seg>Approval of vaccines in the European Union</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Approvazzjoni tal-vaċċini fl-Unjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="79">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Safety, quality and standards</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sikurezza, kwalità ustandards</seg>
</tuv>
</tu>
<tu tuid="80">
<prop type="lengthRatio">0.8536585365853658</prop>
<tuv xml:lang="en">
<seg>Serious side effects are very rare.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Effetti sekondarji serji huma rari ħafna.</seg>
</tuv>
</tu>
<tu tuid="81">
<prop type="lengthRatio">0.9230769230769231</prop>
<tuv xml:lang="en">
<seg>The last known naturally occurring case was recorded in 1977 in Somalia.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-aħħar każ magħruf li seħħ b'mod naturali ġie rreġistrat fl-1977 fis-Somalja.</seg>
</tuv>
</tu>
<tu tuid="82">
<prop type="lengthRatio">0.9221556886227545</prop>
<tuv xml:lang="en">
<seg>Recently, a vaccine was developed against Ebola virus disease, and research is underway on vaccines to protect against human immunodeficiency virus (HIV).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan l-aħħar, ġiet żviluppata tilqima kontra l-virus tal-marda tal-Ebola, u qed issir riċerka dwar tilqim li jipproteġu kontra l-virus tal-immunodefiċjenza umana (HIV).</seg>
</tuv>
</tu>
<tu tuid="83">
<prop type="lengthRatio">1.55</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fatti dwar it-tilqim</seg>
</tuv>
</tu>
<tu tuid="84">
<prop type="lengthRatio">0.920704845814978</prop>
<tuv xml:lang="en">
<seg>The vaccine can only be approved for use in the European Union (EU) and European Economic Area (EEA) after a scientific evaluation of the results of these tests to ensure its quality, safety and effectiveness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqima tista' tiġi approvata biss għall-użu fl-Unjoni Ewropea (UE) u ż-Żona Ekonomika Ewropea (ŻEE) wara evalwazzjoni xjentifika tar-riżultati ta' dawn it-testijiet biex tiżgura l-kwalità, is-sikurezza u l-effikaċja tagħha.</seg>
</tuv>
</tu>
<tu tuid="85">
<prop type="lengthRatio">0.9477611940298507</prop>
<tuv xml:lang="en">
<seg>Vaccines work by ‘teaching' a person's immune system (the body's natural defences) to defend itself against a specific disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jaħdem billi ‘jgħallem' lis-sistema immunitarja (id-difiżi naturali tal-ġisem) biex tiddefendi ruħha kontra marda speċifika.</seg>
</tuv>
</tu>
<tu tuid="86">
<prop type="lengthRatio">0.8125</prop>
<tuv xml:lang="en">
<seg>The vaccine is continuously monitored to ensure it remains safe and effective.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqima tkun qed tiġi ssorveljata kontinwament biex jiġi żgurat li tibqa' sikura u effettiva.</seg>
</tuv>
</tu>
<tu tuid="87">
<prop type="lengthRatio">1.2333333333333334</prop>
<tuv xml:lang="en">
<seg>The first vaccine was developed in the 18th century in the United Kingdom.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ewwel tilqima ġiet żviluppata fis-seklu 18 fir-Renju Unit.</seg>
</tuv>
</tu>
<tu tuid="88">
<prop type="lengthRatio">0.9054054054054054</prop>
<tuv xml:lang="en">
<seg>This evaluation needs to show that a vaccine's benefits in protecting people against diseases are far greater than any potential risk.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din l-evalwazzjoni teħtieġ turi li l-benefiċċji tat-tilqima fil-protezzjoni tan-nies kontra l-mard humaħafna akbar minn kwalunkwe riskju potenzjali.</seg>
</tuv>
</tu>
<tu tuid="89">
<prop type="lengthRatio">0.9193548387096774</prop>
<tuv xml:lang="en">
<seg>The scientific experts evaluating vaccines always consider the benefits and any potential risks very carefully, in particular because vaccines are given to healthy people.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-esperti xjentifiċi li jevalwaw it-tilqim dejjem iqisu l-benefiċċji u kwalunkwe riskju potenzjali b'attenzjoni kbira, b'mod partikolari minħabba tilqim li jingħata lil nies f'saħħithom.</seg>
</tuv>
</tu>
<tu tuid="90">
<prop type="lengthRatio">0.8581560283687943</prop>
<tuv xml:lang="en">
<seg>As with any medicine, some people may experience side effects from a vaccine, but these are usually mild and short-lived.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Bħal kull mediċina oħra, xi wħud min-nies jistgħu jesperjenzaw effetti sekondarji mit-tilqima, iżda dawn ikunu ġeneralment ħfief u ma jdumux.</seg>
</tuv>
</tu>
<tu tuid="91">
<prop type="lengthRatio">0.7642276422764228</prop>
<tuv xml:lang="en">
<seg>Only then, after approval, can a vaccine be manufactured, marketed and used to protect people.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>B'hekk biss, wara l-approvazzjoni, tista' tilqima tiġimanifatturata, titqiegħed fis-suq u tintuża biex tipproteġi lin-nies.</seg>
</tuv>
</tu>
<tu tuid="92">
<prop type="lengthRatio">0.8414634146341463</prop>
<tuv xml:lang="en">
<seg>Smallpox is now eradicated worldwide in humans thanks to vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Qabel kwalunkwe tilqima ġdida tkun tista' tintuża, irid isirilha ttestjar rigoruż.</seg>
</tuv>
</tu>
<tu tuid="93">
<prop type="lengthRatio">0.7878787878787878</prop>
<tuv xml:lang="en">
<seg>It was a vaccine against smallpox, a deadly disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Huwa jimmira l-aktar lejn mard ikkawżat minn viruses jew batterji.</seg>
</tuv>
</tu>
<tu tuid="94">
<prop type="lengthRatio">0.8333333333333334</prop>
<tuv xml:lang="en">
<seg>They can include mild fever, or pain or redness at the injection site.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ġidri, illum il-ġurnatanqerdet mid-dinja kollha fil-bnedmin bis-saħħa tat-tilqim.</seg>
</tuv>
</tu>
<tu tuid="95">
<prop type="lengthRatio">1.064516129032258</prop>
<tuv xml:lang="en">
<seg>They also help to prevent the spread of diseases in the community.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jgħin ukoll fil-prevenzjoni għat-tixrid tal-mard fil-komunità.</seg>
</tuv>
</tu>
<tu tuid="96">
<prop type="lengthRatio">0.7718120805369127</prop>
<tuv xml:lang="en">
<seg>vaccinating against humanpapilloma virus (HPV) can help prevent cervical and other cancers caused by HPV infection;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>it-tilqim kontra l-virus tal-papilloma umana (HPV) jista' jgħin biex jipprevjeni kanċer ċervikali u kanċers oħrajn ikkawżati mill-infezzjoni tal-HPV;</seg>
</tuv>
</tu>
<tu tuid="97">
<prop type="lengthRatio">0.9937888198757764</prop>
<tuv xml:lang="en">
<seg>The connected dots indicate the maximum and minimum number of previously uninfected and unvaccinated people who could get infected by a person with the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tikek magħqudin jindikaw in-numru massimu u minimu ta' persuni mhux infettati u mhux imlaqqma preċedentement li jistgħu jiġu infettati minn persuna bil-marda.</seg>
</tuv>
</tu>
<tu tuid="98">
<prop type="lengthRatio">0.8333333333333334</prop>
<tuv xml:lang="en">
<seg>1-4 people</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Influwenza</seg>
</tuv>
</tu>
<tu tuid="99">
<prop type="lengthRatio">0.8064516129032258</prop>
<tuv xml:lang="en">
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-programmi tat-tilqim għandhom benefiċċji usa' għas-soċjetà.</seg>
</tuv>
</tu>
<tu tuid="100">
<prop type="lengthRatio">0.9122807017543859</prop>
<tuv xml:lang="en">
<seg>vaccinating against hepatitis B can help prevent liver cancer caused by long-term hepatitis B infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>it-tilqim kontra l-epatite B jista' jipprevjeni l-kanċer tal-fwied ikkawżat minn infezzjoni tal-epatite B fit-tul.</seg>
</tuv>
</tu>
<tu tuid="101">
<prop type="lengthRatio">0.8661971830985915</prop>
<tuv xml:lang="en">
<seg>This shows both the most conservative estimate (inner ring, darker dots) and the maximum estimate (outer ring, paler dots).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan juri kemm l-aktar stima konservattiva (ċirku ta' ġewwa, tikek aktar skuri) kif ukoll l-istima massima (ċirku ta' barra, tikek aktar ċari).</seg>
</tuv>
</tu>
<tu tuid="102">
<prop type="lengthRatio">0.8884892086330936</prop>
<tuv xml:lang="en">
<seg>They help reduce the social, psychological and financial burdens of disease on people and governments, reducing pressures on healthcare and social care systems and enabling people to pursue productive activities including education and employment.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jgħinu biex inaqqsu l-piżijiet soċjali, psikoloġiċi u finanzjarji tal-mard fuq in-nies u l-gvernijiet, inaqqsu l-pressjonijiet fuq is-sistemi tal-kura tas-saħħa u tal-kura soċjali u jippermettu lin-nies iwettqu attivitajiet produttivi li jinkludu l-edukazzjoni u l-impjieg.</seg>
</tuv>
</tu>
<tu tuid="103">
<prop type="lengthRatio">1.0476190476190477</prop>
<tuv xml:lang="en">
<seg>Thanks to vaccination:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Bis-saħħa tat-tilqim:</seg>
</tuv>
</tu>
<tu tuid="104">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Vaccination helps prevent the spread of disease in communities.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jgħin jipprevjeni t-tifrix tal-mard fil-komunitajiet.</seg>
</tuv>
</tu>
<tu tuid="105">
<prop type="lengthRatio">1.0092592592592593</prop>
<tuv xml:lang="en">
<seg>Vaccination also prevents the development of certain types of pre-cancerous growths and cancers, for example:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipprevjeni wkoll l-iżvilupp ta' ċerti tipi ta' tkabbir ta' qabel il-kanċer u kanċers, pereżempju:</seg>
</tuv>
</tu>
<tu tuid="106">
<prop type="lengthRatio">0.9795918367346939</prop>
<tuv xml:lang="en">
<seg>When a large percentage of a population is vaccinated, infectious diseases cannot easily spread.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta perċentwal kbir ta' popolazzjoni jiġi mlaqqam, il-mard infettiv ma jistax jinfirex faċilment.</seg>
</tuv>
</tu>
<tu tuid="107">
<prop type="lengthRatio">0.38823529411764707</prop>
<tuv xml:lang="en">
<seg>Fifth Edition 2008, Elsevier Inc.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>it-tixrid tal-poljo ntemm fil-biċċa l-kbira tal-partijiet tad-dinja, inkluż l-Ewropa.</seg>
</tuv>
</tu>
<tu tuid="108">
<prop type="lengthRatio">0.8222222222222222</prop>
<tuv xml:lang="en">
<seg>smallpox is now eradicated worldwide;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-ġidri r-riħ issa nqerdet fid-dinja kollha;</seg>
</tuv>
</tu>
<tu tuid="109">
<prop type="lengthRatio">0.9183673469387755</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni iċċekkja s-sit web tal-ECDC https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="110">
<prop type="lengthRatio">0.9306930693069307</prop>
<tuv xml:lang="en">
<seg>Symptoms usually appear 7 to 10 days after infection, but may also appear up to 21 days later:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-sintomi normalment jidhru 7 sa 10 ijiem wara infezzjoni, iżda jistgħu jidhru wkoll sa 21 jum wara:</seg>
</tuv>
</tu>
<tu tuid="111">
<prop type="lengthRatio">1.0368421052631578</prop>
<tuv xml:lang="en">
<seg>The vaccine for pertussis is usually given in combination with diphtheria and tetanus vaccination (often in combination also with poliomyelitis, Haemophilus influenzae and hepatitis B vaccination).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin għall-pertussis normalment jingħata flimkien mat-tilqima tad-difterite u tat-tetnu (ħafna drabi flimkien ukoll mat-tilqima tal-poljomijelite, Haemophilus influenzae u l-epatite B).</seg>
</tuv>
</tu>
<tu tuid="112">
<prop type="lengthRatio">0.6511627906976745</prop>
<tuv xml:lang="en">
<seg>Who is at risk of pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min qiegħed f'riskju li taqbdu l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="113">
<prop type="lengthRatio">0.9473684210526315</prop>
<tuv xml:lang="en">
<seg>What is pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="114">
<prop type="lengthRatio">0.8159509202453987</prop>
<tuv xml:lang="en">
<seg>In adults and older children, complications include inability to breathe for short periods, broken ribs, rectal prolapse and hernias.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fl-adulti u fi tfal akbar fl-età, il-kumplikazzjonijiet jinkludu n-nuqqas ta' ħila li jieħdu n-nifs għal perjodi qosra, kustilji miksura, prolassi rettali u ernji.</seg>
</tuv>
</tu>
<tu tuid="115">
<prop type="lengthRatio">0.7857142857142857</prop>
<tuv xml:lang="en">
<seg>The most important way to prevent pertussis is through complete immunisation.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-aktar mod importanti ta' kif tiġi pprevenuta l-pertussis huwa permezz ta' immunizzazzjoni sħiħa.</seg>
</tuv>
</tu>
<tu tuid="116">
<prop type="lengthRatio">0.905982905982906</prop>
<tuv xml:lang="en">
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Nota: L-informazzjoni li tinsab f'din l-iskeda informattiva hija maħsuba għall-iskop ta' informazzjoni ġenerali u ma għandhiex tintuża bħala sostitut tal-għarfien espert individwali u tal-ġudizzju ta' professjonist tal-kura tas-saħħa.</seg>
</tuv>
</tu>
<tu tuid="117">
<prop type="lengthRatio">0.8983050847457628</prop>
<tuv xml:lang="en">
<seg>Adolescents, adults, or children partially immunised generally have milder or somewhat different symptoms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-adolexxenti, l-adulti jew it-tfal parzjalment immunizzati ġeneralment ikollhom sintomi eħfef jew xi ftit differenti.</seg>
</tuv>
</tu>
<tu tuid="118">
<prop type="lengthRatio">1.1311475409836065</prop>
<tuv xml:lang="en">
<seg>A primary course of 2-3 doses is usually given between two and twelve months of age, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kors primarju ta' 2-3 dożi normalment jingħata bejn età ta' xahrejn u tnax-il xahar, skont l-iskeda tat-tilqim nazzjonali.</seg>
</tuv>
</tu>
<tu tuid="119">
<prop type="lengthRatio">1.0175438596491229</prop>
<tuv xml:lang="en">
<seg>A third or fourth dose is recommended at 11-24 months of age, and another dose between three and seven years of age.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tielet jew ir-raba' doża hija rakkomandata fl-età ta' 11-24 xahar, u doża oħra bejn età ta' tliet u seba' snin.</seg>
</tuv>
</tu>
<tu tuid="120">
<prop type="lengthRatio">1.0606060606060606</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi tal-pertussis?</seg>
</tuv>
</tu>
<tu tuid="121">
<prop type="lengthRatio">1.02</prop>
<tuv xml:lang="en">
<seg>Within two weeks, the cough becomes more severe and is characterized by episodes of numerous rapid coughs, followed by a crowing or high-pitched ‘whoop'.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Wara din il-fażi, l-episodji tas-sogħla jsiru inqas frekwenti u inqas severi, u t-tarbija bil-mod teqleb għall-aħjar (dan jista' jieħu sa tliet xhur).</seg>
</tuv>
</tu>
<tu tuid="122">
<prop type="lengthRatio">0.9390243902439024</prop>
<tuv xml:lang="en">
<seg>Some EU/EEA countries recommend boosters for adolescents, adults, and/or women during pregnancy, which also temporarily protects the baby once it is born.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi pajjiżi tal-UE/taż-ŻEE jirrakkomandaw boosters għall-adolexxenti, adulti u/jew nisa waqt it-tqala, li temporanjament, jipproteġu wkoll it-tarbija meta titwieled.</seg>
</tuv>
</tu>
<tu tuid="123">
<prop type="lengthRatio">0.9120879120879121</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din tiġi kkawżata minn batterji fil-ħalq, fl-imnieħer u fil-griżmejn ta' persuna infettata.</seg>
</tuv>
</tu>
<tu tuid="124">
<prop type="lengthRatio">1.32</prop>
<tuv xml:lang="en">
<seg>In young infants the typical 'whoop' may never develop, and the coughing fits may be followed by brief periods when breathing stops.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'dawn il-gruppi, u fi trabi żgħar ħafna, il-pertussis hija aktar diffiċli biex tiġi dijanjostikata.</seg>
</tuv>
</tu>
<tu tuid="125">
<prop type="lengthRatio">1.2903225806451613</prop>
<tuv xml:lang="en">
<seg>What are the complications of pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi ttrattata l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="126">
<prop type="lengthRatio">0.9607843137254902</prop>
<tuv xml:lang="en">
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kumplikazzjonijiet jinkludu pulmonite, enċefalopatija (marda tal-moħħ), aċċessjonijiet u anki mewt.</seg>
</tuv>
</tu>
<tu tuid="127">
<prop type="lengthRatio">0.7948717948717948</prop>
<tuv xml:lang="en">
<seg>How can pertussis be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="128">
<prop type="lengthRatio">0.9930555555555556</prop>
<tuv xml:lang="en">
<seg>Pertussis can also be spread by an individual who has only a mild form of the disease, or by an infected individual who has no symptoms at all.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis tista' tinfirex ukoll minn individwu li għandu biss forma ħafifa tal-marda, jew minn individwu infettat li m'għandu l-ebda sintomu.</seg>
</tuv>
</tu>
<tu tuid="129">
<prop type="lengthRatio">0.813953488372093</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din magħrufa wkoll bħala sogħla konvulżiva.</seg>
</tuv>
</tu>
<tu tuid="130">
<prop type="lengthRatio">1.0480769230769231</prop>
<tuv xml:lang="en">
<seg>Initially, symptoms resemble those of a common cold (sneezing, runny nose, low-grade fever and a mild cough).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-bidu, is-sintomi jixbhu dawk ta' riħ komuni (għatis, imnieħer iqattar, deni baxx u sogħla ħafifa).</seg>
</tuv>
</tu>
<tu tuid="131">
<prop type="lengthRatio">0.7623762376237624</prop>
<tuv xml:lang="en">
<seg>It is caused by bacteria in the mouth, nose and throat of an infected person.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis tinfirex minn taqtiriet żgħar fl-arja li jiġu prodotti meta l-persuna infettata tisgħol.</seg>
</tuv>
</tu>
<tu tuid="132">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>Some countries also recommend a booster to unprotected women soon after they have delivered, to reduce the risk of transmission of the disease to the baby.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi pajjiżi jirrakkomandaw ukoll booster għal nisa mhux protetti ftit wara li jkunu welldu, biex jitnaqqas ir-riskju ta' trażmissjoni tal-marda lit-tarbija.</seg>
</tuv>
</tu>
<tu tuid="133">
<prop type="lengthRatio">0.9281045751633987</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated with the pertussis vaccine, or whose vaccination status is not up-to-date, is at risk of contracting the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kwalunkwe persuna li mhijiex imlaqqma bil-vaċċin tal-pertussis, jew li l-istatus tat-tilqim tagħha mhuwiex aġġornat, tinsab f'riskju li taqbadha l-marda.</seg>
</tuv>
</tu>
<tu tuid="134">
<prop type="lengthRatio">1.66</prop>
<tuv xml:lang="en">
<seg>Pertussis is spread via airborne droplets produced when the infected person coughs.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-aktar forom severi tal-pertussis huma fit-trabi.</seg>
</tuv>
</tu>
<tu tuid="135">
<prop type="lengthRatio">0.5376344086021505</prop>
<tuv xml:lang="en">
<seg>The most severe forms of pertussis are in infants.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis hija marda batterika infettiva ħafna li tinvolvi l-pulmun u l-passaġġi tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="136">
<prop type="lengthRatio">1.0909090909090908</prop>
<tuv xml:lang="en">
<seg>the vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>it-tilqima.</seg>
</tuv>
</tu>
<tu tuid="137">
<prop type="lengthRatio">0.9485294117647058</prop>
<tuv xml:lang="en">
<seg>It typically provides lifelong protection and has an effectiveness of around 97-99% among healthy children who receive two doses.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tipikament, din tipprovdi protezzjoni tul il-ħajja u għandha effettività ta' madwar 97-99 % fost tfal b'saħħithom li jirċievu żewġ dożi.</seg>
</tuv>
</tu>
<tu tuid="138">
<prop type="lengthRatio">0.7428571428571429</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety and reporting side effects</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Monitoraġġ tas-sikurezza tal-vaċċin u rappurtar ta' effetti sekondarji</seg>
</tuv>
</tu>
<tu tuid="139">
<prop type="lengthRatio">0.9557522123893806</prop>
<tuv xml:lang="en">
<seg>For example, the vaccine against measles, mumps and rubella (MMR) is highly effective at preventing disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, it-tilqima kontra l-ħosba, il-gattone u r-rubella (MMR) hija effettiva ħafna biex tipprevjeni l-mard.</seg>
</tuv>
</tu>
<tu tuid="140">
<prop type="lengthRatio">0.8725490196078431</prop>
<tuv xml:lang="en">
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ladarba vaċċin jiġi approvat għall-użu, l-awtoritajiet nazzjonali tal-UE/taż-ŻEE u l-Aġenzija Ewropea għall-Mediċini (EMA), jimmonitorjaw kontinwament l-effetti sekondarji fuq in-nies li rċevew il-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="141">
<prop type="lengthRatio">1.1724137931034482</prop>
<tuv xml:lang="en">
<seg>previous contact with the disease;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kuntatt preċedenti mal-marda;</seg>
</tuv>
</tu>
<tu tuid="142">
<prop type="lengthRatio">0.9416666666666667</prop>
<tuv xml:lang="en">
<seg>Vaccines prevent diseases that could otherwise cause serious health problems, permanent disability or even death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini jipprevjenu mard li kieku seta' jikkawża problemi serji tas-saħħa, diżabilità permanenti jew saħansitra mewt.</seg>
</tuv>
</tu>
<tu tuid="143">
<prop type="lengthRatio">0.991304347826087</prop>
<tuv xml:lang="en">
<seg>Authorised vaccines are effective at preventing disease and protecting the population when administered correctly.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim awtorizzat huwa effettiv biex jipprevjeni l-mard u jipproteġi l-popolazzjoni meta jingħata b'mod korrett.</seg>
</tuv>
</tu>
<tu tuid="144">
<prop type="lengthRatio">1.2916666666666667</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-effettività tat-tilqim</seg>
</tuv>
</tu>
<tu tuid="145">
<prop type="lengthRatio">0.8876404494382022</prop>
<tuv xml:lang="en">
<seg>A vaccine's ability to prevent a specific disease determines its effectiveness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kapaċità ta' tilqima li tipprevjeni marda speċifika tiddetermina l-effettività tagħha.</seg>
</tuv>
</tu>
<tu tuid="146">
<prop type="lengthRatio">0.8735632183908046</prop>
<tuv xml:lang="en">
<seg>Individual European countries decide which vaccines should be part of their national vaccination programmes and funded by their national health systems.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pajjiżi Ewropej individwali jiddeċiedu liema vaċċini għandhom ikunu parti mill-programmi nazzjonali tat-tilqim tagħhom u ffinanzjati mis-sistemi tas-saħħa nazzjonali tagħhom.</seg>
</tuv>
</tu>
<tu tuid="147">
<prop type="lengthRatio">1.0982142857142858</prop>
<tuv xml:lang="en">
<seg>In some circumstances, a person can still get a disease even after receiving the recommended doses of a vaccine against it.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, f'dawn il-każijiet, is-sintomi tal-persuna ta' spiss ikunu anqas qawwija minn dawk mingħajr tilqima.</seg>
</tuv>
</tu>
<tu tuid="148">
<prop type="lengthRatio">0.8482758620689655</prop>
<tuv xml:lang="en">
<seg>This is due to the person not developing sufficient protection against the disease or due to immunity decreasing over time.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan huwa dovut għall-fatt li l-persuna ma tkunx żviluppat biżżejjed protezzjoni kontra l-marda jew minħabba li l-immunità tibda tonqos maż-żmien.</seg>
</tuv>
</tu>
<tu tuid="149">
<prop type="lengthRatio">0.671875</prop>
<tuv xml:lang="en">
<seg>They are also less likely to infect others.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Barra minn hekk, hemm probabbiltà anqas li jinfettaw lil oħrajn.</seg>
</tuv>
</tu>
<tu tuid="150">
<prop type="lengthRatio">1.2647058823529411</prop>
<tuv xml:lang="en">
<seg>other diseases or conditions they may have;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>iż-żmien minn mindu jkunu tlaqqmu;</seg>
</tuv>
</tu>
<tu tuid="151">
<prop type="lengthRatio">1.0508474576271187</prop>
<tuv xml:lang="en">
<seg>Effectiveness in an individual depends on a number of factors.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-effettività f'individwu tiddependi fuq għadd ta' fatturi.</seg>
</tuv>
</tu>
<tu tuid="152">
<prop type="lengthRatio">1.7857142857142858</prop>
<tuv xml:lang="en">
<seg>how the vaccine is given;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>l-età tagħhom;</seg>
</tuv>
</tu>
<tu tuid="153">
<prop type="lengthRatio">1.15</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif jaħdmu l-vaċċini</seg>
</tuv>
</tu>
<tu tuid="154">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>These include:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jinkludu:</seg>
</tuv>
</tu>
<tu tuid="155">
<prop type="lengthRatio">1.6</prop>
<tuv xml:lang="en">
<seg>About us</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħosba</seg>
</tuv>
</tu>
<tu tuid="156">
<prop type="lengthRatio">0.6014492753623188</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-infezzjoni tal-virus tal-papilloma uman (HPV) hija infezzjoni virali li tiġi trażmessa l-aktar sesswalment permezz ta' kuntatt dirett...</seg>
</tuv>
</tu>
<tu tuid="157">
<prop type="lengthRatio">0.41904761904761906</prop>
<tuv xml:lang="en">
<seg>For up-to-date information on COVID-19, see:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Qabel ma vaċċin ikun jista' jiġi approvat fl-UE, irid jgħaddi minn ittestjar rigoruż mill-iżviluppatur...</seg>
</tuv>
</tu>
<tu tuid="158">
<prop type="lengthRatio">0.813953488372093</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Approvazzjoni tal-vaċċini fl-Unjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="159">
<prop type="lengthRatio">0.2569832402234637</prop>
<tuv xml:lang="en">
<seg>Rubella (German measles) is a viral infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jipprovdi wkoll ħarsa ġenerali lejn il-mekkaniżmi implimentati fl-Unjoni Ewropea (UE) biex jiġi żgurat li l-vaċċini jikkonformaw mal-ogħla standards ta' sigurtà u effettività.</seg>
</tuv>
</tu>
<tu tuid="160">
<prop type="lengthRatio">0.925</prop>
<tuv xml:lang="en">
<seg>This website does not contain any specific information on the ongoing development of vaccines against COVID-19.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iskop ewlieni ta' dan is-sit web huwa li jipprovdi evidenza preċiża, oġġettiva u aġġornata dwar il-vaċċini u t-tilqim.</seg>
</tuv>
</tu>
<tu tuid="161">
<prop type="lengthRatio">1.7</prop>
<tuv xml:lang="en">
<seg>When to vaccinate</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aqra iktar</seg>
</tuv>
</tu>
<tu tuid="162">
<prop type="lengthRatio">0.5480769230769231</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Wieħed mid-dipartimenti huwa d- DĠ għas-Saħħa u s-Sikurezza Alimentari , responsabbli għall-politika tal-UE dwar is-saħħa u s-sikurezza alimentari u biex jimmonitorja l-implimentazzjoni ta' liġijiet relatati.</seg>
</tuv>
</tu>
<tu tuid="163">
<prop type="lengthRatio">0.9292035398230089</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni ċċekkja s-sit web tal-ECDC: https://www.ecdc.europa.eu/en/human-papillomavirus/factsheet</seg>
</tuv>
</tu>
<tu tuid="164">
<prop type="lengthRatio">1.0666666666666667</prop>
<tuv xml:lang="en">
<seg>Routine HPV vaccination usually takes place between 9 and 14 years of age, in accordance with the national vaccination schedule.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Normalment, it-tilqim ta' rutina kontra l-HPV isir fl-età ta' bejn 9 u 14-il sena, skont l-iskeda ta' tilqim nazzjonali.</seg>
</tuv>
</tu>
<tu tuid="165">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>genital and anal warts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>felul ġenitali u anali</seg>
</tuv>
</tu>
<tu tuid="166">
<prop type="lengthRatio">1.0240963855421688</prop>
<tuv xml:lang="en">
<seg>The use of condoms is not 100% effective in preventing the transmission of the virus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-użu ta' kondoms mhuwiex effettiv 100% fil-prevenzjoni tat-trażmissjoni tal-virus.</seg>
</tuv>
</tu>
<tu tuid="167">
<prop type="lengthRatio">1.0714285714285714</prop>
<tuv xml:lang="en">
<seg>There are more than 100 types of HPV viruses.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hemm aktar minn 100 tip ta' virus ta' HPV.</seg>
</tuv>
</tu>
<tu tuid="168">
<prop type="lengthRatio">0.8461538461538461</prop>
<tuv xml:lang="en">
<seg>Who is at risk of HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min huwa f'riskju ta' HPV?</seg>
</tuv>
</tu>
<tu tuid="169">
<prop type="lengthRatio">0.8809523809523809</prop>
<tuv xml:lang="en">
<seg>If HPV does not go away it may cause:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jekk HPV ma jgħaddix, dan jista' jikkawża:</seg>
</tuv>
</tu>
<tu tuid="170">
<prop type="lengthRatio">0.9230769230769231</prop>
<tuv xml:lang="en">
<seg>Vaccination of girls and boys against HPV can prevent HPV infections and consequently HPV-related diseases in both sexes, including genital and anal warts, cervical cancer and other cancers caused by HPV.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim tal-bniet u tas-subien kontra l-HPV jista' jipprevjeni infezzjonijiet HPV u konsegwentement mard relatat mal-HPV fiż-żewġ sessi, inklużi felul ġenitali u anali, kanċer ċervikali u kanċers oħra kkawżati mill-HPV.</seg>
</tuv>
</tu>
<tu tuid="171">
<prop type="lengthRatio">0.9572649572649573</prop>
<tuv xml:lang="en">
<seg>cervical or other types of cancer (e.g. vulvar, vaginal, anal penile, and some cancers of the head and the neck)</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kanċer ċervikali jew tipi oħra ta' kanċers (eż. vulvari, vaġinali, anali, tal-pene, u xi kanċers tar-ras u tal-għonq)</seg>
</tuv>
</tu>
<tu tuid="172">
<prop type="lengthRatio">0.8607594936708861</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact with an infected person.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-infezzjoni tal-virus tal-papilloma uman (HPV) hija infezzjoni virali li tiġi trażmessa l-aktar sesswalment permezz ta' kuntatt dirett ma' persuna infettata.</seg>
</tuv>
</tu>
<tu tuid="173">
<prop type="lengthRatio">0.7733333333333333</prop>
<tuv xml:lang="en">
<seg>The 'low risk' HPV types can cause genital and anal warts.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tipi ta' HPV ta' "riskju baxx" jistgħu jikkawżaw felul ġenitali u anali.</seg>
</tuv>
</tu>
<tu tuid="174">
<prop type="lengthRatio">0.5</prop>
<tuv xml:lang="en">
<seg>What is HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif jiġi ttrattat l-HPV?</seg>
</tuv>
</tu>
<tu tuid="175">
<prop type="lengthRatio">1.0740740740740742</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi ta' HPV?</seg>
</tuv>
</tu>
<tu tuid="176">
<prop type="lengthRatio">0.8711656441717791</prop>
<tuv xml:lang="en">
<seg>Cervical cancer (cancer of the neck of the womb) is the most common cancer after breast cancer to affect women aged 15-44 years in Europe (1).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kanċer ċervikali (kanċer tal-għonq tal-utru) huwa l-aktar kanċer komuni wara l-kanċer tas-sider li jaffettwa n-nisa li għandhom bejn 15 u 44 sena fl-Ewropa (1).</seg>
</tuv>
</tu>
<tu tuid="177">
<prop type="lengthRatio">0.8778625954198473</prop>
<tuv xml:lang="en">
<seg>There is no treatment for the virus itself, but the health problems caused by HPV can be treated in different ways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>M'hemm l-ebda trattament għall-virus innifsu, iżda l-problemi tas-saħħa kkawżati mill-HPV jistgħu jiġu ttrattati b'modi differenti.</seg>
</tuv>
</tu>
<tu tuid="178">
<prop type="lengthRatio">0.7769230769230769</prop>
<tuv xml:lang="en">
<seg>At least 14 HPV types, classified as ‘high risk', can cause cancer, such as cervical cancer in women.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tal-inqas 14-il tip ta' HPV, ikklassifikati bħala ta' "riskju għoli", jistgħu jikkawżaw il-kanċer, bħal kanċer ċervikali fin-nisa.</seg>
</tuv>
</tu>
<tu tuid="179">
<prop type="lengthRatio">0.8421052631578947</prop>
<tuv xml:lang="en">
<seg>The ‘high risk' HPV types can also cause anal and genital cancers, and some cancers of the head and neck, in both men and women.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tipi ta' HPV ta' "riskju għoli" jistgħu jikkawżaw ukoll kanċer anali u ġenitali, u xi kanċers tar-ras u tal-għonq, kemm fl-irġiel kif ukoll fin-nisa.</seg>
</tuv>
</tu>
<tu tuid="180">
<prop type="lengthRatio">0.5588235294117647</prop>
<tuv xml:lang="en">
<seg>How is HPV treated?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-HPV, kif tista' tiġi pprevenuta?</seg>
</tuv>
</tu>
<tu tuid="181">
<prop type="lengthRatio">0.7317073170731707</prop>
<tuv xml:lang="en">
<seg>Genital warts can be treated using medication or by surgery.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-felul ġenitali jista' jiġi ttrattat permezz ta' medikazzjoni jew b'operazzjoni.</seg>
</tuv>
</tu>
<tu tuid="182">
<prop type="lengthRatio">0.8613861386138614</prop>
<tuv xml:lang="en">
<seg>A healthcare provider should be consulted for advice on the specific treatment options.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għandu jiġi kkonsultat fornitur tal-kura tas-saħħa għal parir dwar għażliet ta' trattament speċifiċi.</seg>
</tuv>
</tu>
<tu tuid="183">
<prop type="lengthRatio">0.7313432835820896</prop>
<tuv xml:lang="en">
<seg>Cervical cancer and tissue in the cervix that is described as ‘precancerous' can be identified early through cervical cancer screening and treated.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kanċer ċervikali u tessut fl-għonq tal-utru li huwa deskritt bħala "ta' qabel il-kanċer" jistgħu jiġu identifikati fi stadju bikri permezz ta' skrinjar tal-kanċer ċervikali u jistgħu jiġu ttrattati.</seg>
</tuv>
</tu>
<tu tuid="184">
<prop type="lengthRatio">0.7790055248618785</prop>
<tuv xml:lang="en">
<seg>Other HPV-related cancers are also more treatable when diagnosed and treated early, but there are no specific screening programmes for these.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kanċers oħra relatati mal-HPV jistgħu wkoll jiġu ttrattati aktar meta jiġu ddijanjostikati u ttrattati fi stadju kmieni, iżda m'hemm l-ebda programm ta' skrinjar speċifiku għalihom.</seg>
</tuv>
</tu>
<tu tuid="185">
<prop type="lengthRatio">0.9438202247191011</prop>
<tuv xml:lang="en">
<seg>HPV is transmitted by direct contact, mainly sexual, with someone who has the virus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-HPV jiġi trażmess b'kuntatt dirett, l-aktar sesswalment, ma' xi ħadd li għandu l-virus.</seg>
</tuv>
</tu>
<tu tuid="186">
<prop type="lengthRatio">0.8823529411764706</prop>
<tuv xml:lang="en">
<seg>Anyone who is sexually active is at risk of contracting HPV.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull min hu sesswalment attiv huwa f'riskju li jiġi infettat bl-HPV.</seg>
</tuv>
</tu>
<tu tuid="187">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>What are the complications of HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma l-kumplikazzjoni ta' HPV?</seg>
</tuv>
</tu>
<tu tuid="188">
<prop type="lengthRatio">0.8313253012048193</prop>
<tuv xml:lang="en">
<seg>This is offered to women in accordance with national recommendations.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hija l-aktar infezzjoni li tiġi trażmessa sesswalment b'mod komuni madwar id-dinja.</seg>
</tuv>
</tu>
<tu tuid="189">
<prop type="lengthRatio">0.8148148148148148</prop>
<tuv xml:lang="en">
<seg>The person is also at risk of complications.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-persuna tkun ukoll f'riskju ta' kumplikazzjonijiet.</seg>
</tuv>
</tu>
<tu tuid="190">
<prop type="lengthRatio">1.0677966101694916</prop>
<tuv xml:lang="en">
<seg>Immunity usually lasts for years, and sometimes for a lifetime.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-immunità normalment iddum snin, u xi drabi tul ta' ħajja.</seg>
</tuv>
</tu>
<tu tuid="191">
<prop type="lengthRatio">1.08</prop>
<tuv xml:lang="en">
<seg>This is called the antigen.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jissejjaħ l-antiġene.</seg>
</tuv>
</tu>
<tu tuid="192">
<prop type="lengthRatio">1.0307692307692307</prop>
<tuv xml:lang="en">
<seg>Each virus and bacterium triggers a unique response in the immune system involving a specific set of cells in the blood, in the bone marrow and all over the body, called T-cells, B-cells, among others.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull virus u batterju joħloq reazzjoni unika fis-sistema immunitarja li tinvolvi sett speċifiku ta' ċelloli fid-demm, fil-mudullun u mal-ġisem kollu, imsejħa ċelloli T u ċelloli B, fost l-oħrajn.</seg>
</tuv>
</tu>
<tu tuid="193">
<prop type="lengthRatio">0.918918918918919</prop>
<tuv xml:lang="en">
<seg>Antibodies are special proteins that help kill the infectious agent.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Antikorpi huma proteini speċjali li jgħinu biex jinqatel l-aġent infettiv.</seg>
</tuv>
</tu>
<tu tuid="194">
<prop type="lengthRatio">1.2916666666666667</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-komponenti tal-vaċċin</seg>
</tuv>
</tu>
<tu tuid="195">
<prop type="lengthRatio">1.0625</prop>
<tuv xml:lang="en">
<seg>How vaccines work</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Reazzjoni immuni</seg>
</tuv>
</tu>
<tu tuid="196">
<prop type="lengthRatio">1.0185185185185186</prop>
<tuv xml:lang="en">
<seg>Vaccines contain a greatly weakened or an inactivated (killed) form of a virus or bacterium that usually causes a disease, or a small part of the virus or bacterium.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini fihom forma mdgħajfa ħafna jew inattivata (maqtula) ta' virus jew batterju li normalment jikkawża marda, jew parti żgħira mill-virus jew mill-batterju.</seg>
</tuv>
</tu>
<tu tuid="197">
<prop type="lengthRatio">0.9692307692307692</prop>
<tuv xml:lang="en">
<seg>Later, if the person comes into contact with the actual infectious virus or bacterium, their immune system will ‘remember' it.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aktar tard, jekk il-persuna tiġi f'kuntatt mal-virus jew mal-batterju infettiv attwali, is-sistema immunitarja tagħhom "tiftakru".</seg>
</tuv>
</tu>
<tu tuid="198">
<prop type="lengthRatio">0.9728260869565217</prop>
<tuv xml:lang="en">
<seg>Immunity through vaccination protects not only the immunised individual but also protects unvaccinated people in the community, such as infants who are too young to be vaccinated.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-immunità permezz tat-tilqim tipproteġi mhux biss lill-individwu immunizzat iżda tipproteġi wkoll lin-nies mhux imlaqqma fil-komunità, bħat-trabi li huma żgħar wisq biex jiġu mlaqqma.</seg>
</tuv>
</tu>
<tu tuid="199">
<prop type="lengthRatio">0.9289940828402367</prop>
<tuv xml:lang="en">
<seg>It will then quickly produce the right antibodies and activate the right immune cells to kill the virus or bacterium, protecting the person from the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din imbagħad tipproduċi malajr l-antikorpi x-xierqa u tattiva ċ-ċelloli immuni x-xierqa biex joqtlu l-virus jew il-batterju, u b'hekk tipproteġi lill-persuna mill-marda.</seg>
</tuv>
</tu>
<tu tuid="200">
<prop type="lengthRatio">1.1018518518518519</prop>
<tuv xml:lang="en">
<seg>A vaccine stimulates an immune response, and a ‘memory' of the body to a specific disease, without causing the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Vaċċin jistimula reazzjoni immuni, u "memorja" tal-ġisem għal marda speċifika, mingħajr ma jikkawża l-marda.</seg>
</tuv>
</tu>
<tu tuid="201">
<prop type="lengthRatio">0.9484536082474226</prop>
<tuv xml:lang="en">
<seg>When a person is given the vaccine, their immune system recognises the antigen as ‘foreign'.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta persuna tingħata l-vaċċin, is-sistema immunitarja tagħha tagħraf l-antiġene bħala "barrani".</seg>
</tuv>
</tu>
<tu tuid="202">
<prop type="lengthRatio">0.978494623655914</prop>
<tuv xml:lang="en">
<seg>The immune cells are trained to kill and make antibodies against the disease-causing agent.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Iċ-ċelloli immuni huma mħarrġa joqtlu u joħolqu antikorpi kontra l-aġent li jikkawża l-marda.</seg>
</tuv>
</tu>
<tu tuid="203">
<prop type="lengthRatio">0.891566265060241</prop>
<tuv xml:lang="en">
<seg>This ‘ community immunity ' can only work if enough people are vaccinated.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din l-" immunità komunitarja " tista' taħdem biss jekk jiġu mlaqqma biżżejjed nies.</seg>
</tuv>
</tu>
<tu tuid="204">
<prop type="lengthRatio">0.9747899159663865</prop>
<tuv xml:lang="en">
<seg>In contrast, a person who becomes immune by getting the disease can expose other unvaccinated people to the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>B'kuntrast għal dan, persuna li ssir immuni billi tieħu l-marda tista' tesponi lil nies oħra mhux imlaqqma għall-marda.</seg>
</tuv>
</tu>
<tu tuid="205">
<prop type="lengthRatio">0.9310344827586207</prop>
<tuv xml:lang="en">
<seg>National governments take account of factors such as their health systems, legal systems and cultural norms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-gvernijiet nazzjonali jikkunsidraw fatturi bħas-sistemi tas-saħħa, is-sistemi legali u n-normi kulturali tagħhom.</seg>
</tuv>
</tu>
<tu tuid="206">
<prop type="lengthRatio">1.0543478260869565</prop>
<tuv xml:lang="en">
<seg>Information on which countries have mandatory vaccination can be found in the Vaccine Scheduler .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni dwar liema pajjiżi għandhom tilqim obbligatorju tinsab fl-Aġenda tal-Vaċċini .</seg>
</tuv>
</tu>
<tu tuid="207">
<prop type="lengthRatio">1.0606060606060606</prop>
<tuv xml:lang="en">
<seg>Vaccination schedules in the EU/EEA</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iskedi tat-tilqim fl-UE/fiż-ŻEE</seg>
</tuv>
</tu>
<tu tuid="208">
<prop type="lengthRatio">0.972972972972973</prop>
<tuv xml:lang="en">
<seg>Mandatory or recommended vaccination</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tilqim obbligatorju jew irrakkomandat</seg>
</tuv>
</tu>
<tu tuid="209">
<prop type="lengthRatio">0.7469879518072289</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country implements its own immunisation programme.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull pajjiż tal-UE/taż-ŻEE jimplimenta l-programm ta' immunizzazzjoni tiegħu stess.</seg>
</tuv>
</tu>
<tu tuid="210">
<prop type="lengthRatio">0.7818181818181819</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country decides if vaccination is mandatory or voluntary in its territory.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull pajjiż tal-UE/taż-ŻEE jiddeċiedi jekk it-tilqim huwiex obbligatorju jew volontarju fit-territorju tiegħu.</seg>
</tuv>
</tu>
<tu tuid="211">
<prop type="lengthRatio">0.9221556886227545</prop>
<tuv xml:lang="en">
<seg>In 12 EU/EEA countries, vaccinating children against some diseases is mandatory, although different vaccines are required as mandatory in those countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fi 12-il pajjiż tal-UE/taż-ŻEE, it-tilqim tat-tfal kontra ċertu mard huwa obbligatorju, għalkemm vaċċini differenti huma meħtieġa bħala obbligatorji f'dawn il-pajjiżi.</seg>
</tuv>
</tu>
<tu tuid="212">
<prop type="lengthRatio">0.8809523809523809</prop>
<tuv xml:lang="en">
<seg>EU/EEA countries have achieved high vaccination coverage rates through mandatory and non-mandatory vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pajjiżi tal-UE/taż-ŻEE kisbu rati għoljin ta' kopertura ta' tilqim permezz tat-tilqim obbligatorju u dak mhux obbligatorju.</seg>
</tuv>
</tu>
<tu tuid="213">
<prop type="lengthRatio">0.7875</prop>
<tuv xml:lang="en">
<seg>Most EU/EEA countries offer vaccination on a recommended basis.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-maġġoranza tal-pajjiżi tal-UE/taż-ŻEE joffru t-tilqim fuq bażi rrakkomandata.</seg>
</tuv>
</tu>
<tu tuid="214">
<prop type="lengthRatio">0.8142076502732241</prop>
<tuv xml:lang="en">
<seg>Each EU/EEA country is responsible for its own national public health policy, including its national immunisation programme and vaccination schedule.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull pajjiż tal-UE/taż-ŻEE huwa responsabbli għall-politika nazzjonali tas-saħħa pubblika tiegħu stess, inkluż il-programm nazzjonali ta' immunizzazzjoni u l-iskeda tat-tilqim tiegħu.</seg>
</tuv>
</tu>
<tu tuid="215">
<prop type="lengthRatio">0.9455128205128205</prop>
<tuv xml:lang="en">
<seg>These may include the age and population to be vaccinated (for example, all children of a certain age or only those in a risk group), the exact type of vaccine (e.g. some ingredients may differ), the number and timing of doses, and whether a vaccine is given alone or in combination with others.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jistgħu jinkludu l-età u l-popolazzjoni li għandha tiġi mlaqqma (pereżempju, it-tfal kollha ta' ċerta età jew dawk li jinsabu fi grupp ta' riskju biss), it-tip eżatt tal-vaċċin (eż. xi ingredjenti jistgħu jvarjaw), in-numru u meta jingħataw id-dożi, u jekk il-vaċċin jingħatax waħdu jew flimkien ma' oħrajn.</seg>
</tuv>
</tu>
<tu tuid="216">
<prop type="lengthRatio">0.9888888888888889</prop>
<tuv xml:lang="en">
<seg>Factors driving such differences may include the disease's burden, prevalence of the disease and trends in different countries, the resources and structures of healthcare systems, political and cultural factors, as well as the resilience of the vaccination programme.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fatturi li jixprunaw differenzi bħal dawn jistgħu jinkludu l-piż tal-marda, il-prevalenza tal-marda u x-xejriet f'pajjiżi differenti, ir-riżorsi u l-istrutturi tas-sistemi tal-kura tas-saħħa, fatturi politiċi u kulturali, kif ukoll ir-reżiljenza tal-programm tat-tilqim.</seg>
</tuv>
</tu>
<tu tuid="217">
<prop type="lengthRatio">0.95</prop>
<tuv xml:lang="en">
<seg>Information on the national vaccination schedules in EU/EEA countries can be found in the ECDC Vaccine Scheduler .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni dwar l-iskedi tat-tilqim nazzjonali fil-pajjiżi tal-UE/taż-ŻEE tinstab fl-Iskedatur tal-Vaċċini tal-ECDC .</seg>
</tuv>
</tu>
<tu tuid="218">
<prop type="lengthRatio">0.863013698630137</prop>
<tuv xml:lang="en">
<seg>The same level of protection is ensured in each EU/EEA country.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-istess livell ta' protezzjoni jiġi żgurat f'kull pajjiż tal-UE/taż-ŻEE.</seg>
</tuv>
</tu>
<tu tuid="219">
<prop type="lengthRatio">0.9681528662420382</prop>
<tuv xml:lang="en">
<seg>There are some differences in the way countries organise their vaccination schedules, which are similar but not identical in different EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hemm xi differenzi fil-mod ta' kif il-pajjiżi jorganizzaw l-iskedi tat-tilqim tagħhom, li huma simili iżda mhux identiċi f'pajjiżi differenti tal-UE/taż-ŻEE.</seg>
</tuv>
</tu>
<tu tuid="220">
<prop type="lengthRatio">1.010989010989011</prop>
<tuv xml:lang="en">
<seg>The childhood vaccination schedules in all EU/EEA countries include the vaccination against:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-iskedi tat-tilqim fit-tfulija fil-pajjiżi kollha tal-UE/taż-ŻEE jinkludu t-tilqim kontra:</seg>
</tuv>
</tu>
<tu tuid="221">
<prop type="lengthRatio">0.9594594594594594</prop>
<tuv xml:lang="en">
<seg>They just take into account different circumstances and health systems.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn sempliċiment jikkunsidraw ċirkostanzi u sistemi tas-saħħa differenti.</seg>
</tuv>
</tu>
<tu tuid="222">
<prop type="lengthRatio">1.0714285714285714</prop>
<tuv xml:lang="en">
<seg>Vaccines in the national schedules are given in the appropriate timeframes to ensure adequate protection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini fl-iskedi nazzjonali jingħataw fiż-żminijiet xierqa biex jiżguraw protezzjoni adegwata.</seg>
</tuv>
</tu>
<tu tuid="223">
<prop type="lengthRatio">3.875</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-ħosba</seg>
</tuv>
</tu>
<tu tuid="224">
<prop type="lengthRatio">0.9607843137254902</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/measles/facts/factsheet</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni ara s-sit web tal-ECDC: https://www.ecdc.europa.eu/en/measles/facts/factsheet</seg>
</tuv>
</tu>
<tu tuid="225">
<prop type="lengthRatio">3.0</prop>
<tuv xml:lang="en">
<seg>More factsheets</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħosba</seg>
</tuv>
</tu>
<tu tuid="226">
<prop type="lengthRatio">0.9852941176470589</prop>
<tuv xml:lang="en">
<seg>on the third to seventh day, the temperature may reach up to 41 ⁰C;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>bejn it-tielet u s-seba' jum, it-temperatura tista' titla' sa 41 ⁰C;</seg>
</tuv>
</tu>
<tu tuid="227">
<prop type="lengthRatio">0.8984375</prop>
<tuv xml:lang="en">
<seg>Symptoms include personality changes, gradual mental deterioration, muscle spasms and other neuromuscular symptoms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-sintomi jinkludu tibdiliet fil-personalità, deterjorament mentali gradwali, spażmi tal-muskoli u sintomi newromuskolari oħra.</seg>
</tuv>
</tu>
<tu tuid="228">
<prop type="lengthRatio">0.6666666666666666</prop>
<tuv xml:lang="en">
<seg>Who is at risk of measles?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min qiegħed f'riskju li taqbdu l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="229">
<prop type="lengthRatio">0.9315068493150684</prop>
<tuv xml:lang="en">
<seg>The MMR (measles, mumps and rubella) vaccine is a combination vaccine that protects against measles, mumps and rubella (German measles).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR (il-ħosba, il-gattone u r-rubella) huwa vaċċin ikkombinat li jipproteġi kontra l-ħosba, il-gattone u r-rubella (il-ħosba Ġermaniża).</seg>
</tuv>
</tu>
<tu tuid="230">
<prop type="lengthRatio">0.8493150684931506</prop>
<tuv xml:lang="en">
<seg>Measles symptoms usually appear after 10-12 days of infection:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Is-sintomi tal-ħosba normalment jidhru wara 10-12-il jum mill-infezzjoni:</seg>
</tuv>
</tu>
<tu tuid="231">
<prop type="lengthRatio">0.8881118881118881</prop>
<tuv xml:lang="en">
<seg>Very rarely, a persistent measles virus infection can produce subacute sclerosing panencephalitis (SSPE), a disease in which nerves and brain tissue degenerate progressively and which is more likely to appear if measles infection occurs at a younger age.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'każijiet rarissimi, infezzjoni persistenti bil-virus tal-ħosba tista' tipproduċi panenċefalite sklerożanti subakuta (SSPE), marda li fiha n-nervi u t-tessut tal-moħħ jiddeġeneraw b'mod progressiv u li għandha probabbiltà akbar li tidher jekk l-infezzjoni bil-ħosba sseħħ f'età iżgħar.</seg>
</tuv>
</tu>
<tu tuid="232">
<prop type="lengthRatio">0.8823529411764706</prop>
<tuv xml:lang="en">
<seg>30% of children and adults infected with measles can develop complications.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>30% tat-tfal u tal-adulti infettati bil-ħosba jistgħu jiżviluppaw kumplikazzjonijiet.</seg>
</tuv>
</tu>
<tu tuid="233">
<prop type="lengthRatio">0.9177489177489178</prop>
<tuv xml:lang="en">
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Nota: L-informazzjoni li tinsab f'din l-iskeda informattiva hija maħsuba għall-iskop ta' informazzjoni ġenerali u ma għandhiex tintuża bħala sostitut tal-għarfien espert individwali u tal-ġudizzju ta' professjonist fil-kura medika.</seg>
</tuv>
</tu>
<tu tuid="234">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>It is estimated that one person with measles can infect on average between 12 and 18 unprotected people.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Huwa stmat li persuna waħda bil-ħosba tista' tinfetta bħala medja bejn 12 u 18-il persuna mhux protetta.</seg>
</tuv>
</tu>
<tu tuid="235">
<prop type="lengthRatio">0.9871794871794872</prop>
<tuv xml:lang="en">
<seg>The mortality rate for measles is 1-3 persons per 1 000 cases and highest in those younger than five years of age and among immunocompromised individuals.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-rata ta' mortalità għall-ħosba hija ta' persuna sa tlieta għal kull 1 000 każ u l-ogħla f'dawk iżgħar minn ħames snin u fost individwi immunokompromessi.</seg>
</tuv>
</tu>
<tu tuid="236">
<prop type="lengthRatio">0.9279279279279279</prop>
<tuv xml:lang="en">
<seg>The measles virus is spread via airborne droplets produced when the infected person coughs and sneezes.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-virus tal-ħosba jinfirex minn taqtiriet fl-arja li jiġu prodotti meta l-persuna infettata tisgħol u tagħtas.</seg>
</tuv>
</tu>
<tu tuid="237">
<prop type="lengthRatio">0.9473684210526315</prop>
<tuv xml:lang="en">
<seg>Measles spreads easily among unvaccinated individuals.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ħosba tinfirex faċilment fost individwi mhux imlaqqma.</seg>
</tuv>
</tu>
<tu tuid="238">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>A person who is infected may transmit measles even before the rash appears (usually 4 days), and for about 4 days after the rash has appeared.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Persuna infettata tista' tittrażmetti l-ħosba anki qabel ma jidher ir-raxx (normalment 4 ijiem), u għal madwar 4 ijiem wara li jidher ir-raxx.</seg>
</tuv>
</tu>
<tu tuid="239">
<prop type="lengthRatio">0.8285714285714286</prop>
<tuv xml:lang="en">
<seg>How can measles be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="240">
<prop type="lengthRatio">0.9047619047619048</prop>
<tuv xml:lang="en">
<seg>SSPE typically appears several years after the affected patient had measles; on average it is seen 7 to 10 years after the infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-SSPE tipikament tidher wara bosta snin wara li l-pazjent affettwat ikollu l-ħosba; bħala medja, tiġi osservata wara 7 sa 10 snin mill-infezzjoni.</seg>
</tuv>
</tu>
<tu tuid="241">
<prop type="lengthRatio">0.912621359223301</prop>
<tuv xml:lang="en">
<seg>About 1 measles patient in 1 000 develops inflammation of the brain tissue (encephalitis), a condition that results in permanent neurological disability in approximately one of four cases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madwar pazjent wieħed bil-ħosba minn 1 000 jiżviluppa infjammazzjoni tat-tessut tal-moħħ (enċefalite), kundizzjoni li twassal għal diżabilità newroloġika permanenti f'madwar wieħed minn kull erba' każijiet.</seg>
</tuv>
</tu>
<tu tuid="242">
<prop type="lengthRatio">0.972972972972973</prop>
<tuv xml:lang="en">
<seg>Virus-containing droplets can remain in the air for several hours and the virus remains infectious on contaminated surfaces for up to two hours.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Taqtiriet li jkun fihom il-virus jistgħu jibqgħu fl-arja għal diversi sigħat u l-virus jibqa' infettiv fuq uċuħ kontaminati sa massimu ta' sagħtejn.</seg>
</tuv>
</tu>
<tu tuid="243">
<prop type="lengthRatio">0.9629629629629629</prop>
<tuv xml:lang="en">
<seg>Antibiotics are not effective against measles because it is caused by a virus.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-antibijotiċi mhumiex effettivi kontra l-ħosba għaliex hija kkawżata minn virus.</seg>
</tuv>
</tu>
<tu tuid="244">
<prop type="lengthRatio">0.9836065573770492</prop>
<tuv xml:lang="en">
<seg>Pneumonia is the most common cause of measles-related death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-protezzjoni massima huma meħtieġa żewġ dożi tal-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="245">
<prop type="lengthRatio">1.21875</prop>
<tuv xml:lang="en">
<seg>Anyone who is not vaccinated against measles or who has not had the disease is at risk of getting measles at any age.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħafna nies jirkupraw b'kura ta' sostenn, li tista' tinkludi idrazzjoni u mediċini kontra d-deni.</seg>
</tuv>
</tu>
<tu tuid="246">
<prop type="lengthRatio">1.1379310344827587</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of measles?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi tal-ħosba?</seg>
</tuv>
</tu>
<tu tuid="247">
<prop type="lengthRatio">0.8324607329842932</prop>
<tuv xml:lang="en">
<seg>However, antibiotics are often used to treat complications with bacterial infections that can develop because of measles, such as pneumonia and ear infections.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, l-antibijotiċi spiss jintużaw sabiex jikkuraw kumplikazzjonijiet b'infezzjonijiet batterjali li jistgħu jiżviluppaw minħabba l-ħosba, bħall-pulmonite u infezzjonijiet tal-widnejn.</seg>
</tuv>
</tu>
<tu tuid="248">
<prop type="lengthRatio">0.7563451776649747</prop>
<tuv xml:lang="en">
<seg>Some vaccine recipients develop a non-infectious mild measles-like rash, typically 7 - 14 days after vaccination, which disappears within 1 - 3 days.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi wħud minn dawk li jingħataw il-vaċċin jiżviluppaw raxx ħafif mhux infettiv li jixbah lill-ħosba, tipikament bejn sebat ijiem u 14-il jum wara t-tilqim, li jisparixxi bejn jum u tlett ijiem wara.</seg>
</tuv>
</tu>
<tu tuid="249">
<prop type="lengthRatio">1.0408163265306123</prop>
<tuv xml:lang="en">
<seg>The only protection against measles is vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-unika protezzjoni kontra l-ħosba hija t-tilqim.</seg>
</tuv>
</tu>
<tu tuid="250">
<prop type="lengthRatio">0.7966101694915254</prop>
<tuv xml:lang="en">
<seg>These can include ear infections and diarrhoea.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn jistgħu jinkludu infezzjonijiet tal-widnejn u dijarea.</seg>
</tuv>
</tu>
<tu tuid="251">
<prop type="lengthRatio">0.981651376146789</prop>
<tuv xml:lang="en">
<seg>Measles is a highly contagious viral disease that can be contracted at any age, and that can spread widely.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ħosba hija marda virali kuntaġġuża ħafna li tista' tittieħed fi kwalunkwe età, u li tista' tinfirex ħafna.</seg>
</tuv>
</tu>
<tu tuid="252">
<prop type="lengthRatio">1.2222222222222223</prop>
<tuv xml:lang="en">
<seg>There is no cure for SSPE and it always leads to death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ma teżisti l-ebda kura speċifika għall-ħosba.</seg>
</tuv>
</tu>
<tu tuid="253">
<prop type="lengthRatio">1.6304347826086956</prop>
<tuv xml:lang="en">
<seg>initial symptoms resemble a cold with a runny nose, cough and a mild fever;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>l-għajnejn isiru ħomor u sensittivi għad-dawl;</seg>
</tuv>
</tu>
<tu tuid="254">
<prop type="lengthRatio">1.25</prop>
<tuv xml:lang="en">
<seg>a red rash lasting four to seven days begins on the face and then spreads over the entire body;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>jistgħu jidhru wkoll ponot bojod żgħar fuq il-ħanek u fuq ġewwa tal-ħaddejn.</seg>
</tuv>
</tu>
<tu tuid="255">
<prop type="lengthRatio">1.0508474576271187</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine may be given earlier in life during outbreaks.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR tista' tingħata aktar kmieni matul tifqigħat.</seg>
</tuv>
</tu>
<tu tuid="256">
<prop type="lengthRatio">0.9032258064516129</prop>
<tuv xml:lang="en">
<seg>Vaccination against pertussis is part of national immunisation programmes in the EU.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tlaqqim kontra l-pertussis huwa parti minn programmi nazzjonali ta' immunizzazzjoni fl-UE.</seg>
</tuv>
</tu>
<tu tuid="257">
<prop type="lengthRatio">1.0127659574468084</prop>
<tuv xml:lang="en">
<seg>For example, during 2018 about 86% of infants worldwide received three doses of the vaccine that protects them against diphtheria, tetanus and pertussis (DTP), and 85% of infants around the world received three doses of polio vaccine (1).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, matul l-2018 madwar 86 % tat-trabi madwar id-dinja rċevew tliet dożi tal-vaċċin li jipproteġihom mid-difterite, it-tetnu u l-pertussis (DTP), u 85 % tat-trabi madwar id-dinja rċevew tliet dożi tal-vaċċin kontra l-poljo (1).</seg>
</tuv>
</tu>
<tu tuid="258">
<prop type="lengthRatio">1.0555555555555556</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine is safe and effective.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR huwa sikur u effettiv.</seg>
</tuv>
</tu>
<tu tuid="259">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>This protects children from whooping cough, while it only causes minor side effects.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jipproteġi lit-tfal mis-sogħla konvulżiva, filwaqt li jikkawża biss effetti sekondarji minuri.</seg>
</tuv>
</tu>
<tu tuid="260">
<prop type="lengthRatio">0.9058823529411765</prop>
<tuv xml:lang="en">
<seg>The MMR vaccine protects against measles, mumps and rubella (German measles).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin MMR jipproteġi kontra l-ħosba, il-gattone u r-rubella (il-ħosba Ġermaniża).</seg>
</tuv>
</tu>
<tu tuid="261">
<prop type="lengthRatio">0.90625</prop>
<tuv xml:lang="en">
<seg>Less than 5% will have fever.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Inqas minn 5 % ikollhom id-deni.</seg>
</tuv>
</tu>
<tu tuid="262">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>It will often lead to hospitalisation in infants, and the risk of complications and hospitalisation increases for infants younger than three months.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ta' spiss twassal għal ospitalizzazzjoni fit-trabi, u r-riskju ta' komplikazzjonijiet u ospitalizzazzjoni jiżdied għal trabi iżgħar minn tliet xhur.</seg>
</tuv>
</tu>
<tu tuid="263">
<prop type="lengthRatio">0.6619718309859155</prop>
<tuv xml:lang="en">
<seg>For more information, see pertussis factsheet .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni, ara l-iskeda informattiva dwar il-pertussis .</seg>
</tuv>
</tu>
<tu tuid="264">
<prop type="lengthRatio">0.9272727272727272</prop>
<tuv xml:lang="en">
<seg>Complications can include pneumonia, encephalopathy (a disease of the brain), seizures and even death.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-komplikazzjonijiet jistgħu jinkludu pulmonite, enċefalopatija (marda tal-moħħ), aċċessjonijiet u anki mewt.</seg>
</tuv>
</tu>
<tu tuid="265">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>About 20% of infants will have redness and pain at the injection site.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madwar 20 % tat-trabi jkollhom ħmurija u wġigħ fis-sit tal-injezzjoni.</seg>
</tuv>
</tu>
<tu tuid="266">
<prop type="lengthRatio">1.0718954248366013</prop>
<tuv xml:lang="en">
<seg>However, since October 2016 a resurgence of measles has been observed in the EU/EEA, with outbreaks in several countries (2), due to a decline in vaccination rates.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, minn Ottubru 2016 ġie osservat ritorn ġdid tal-ħosba fl-UE/fiż-ŻEE, b'tifqigħat f'diversi pajjiżi (2), minħabba tnaqqis fir-rati tat-tlaqqim.</seg>
</tuv>
</tu>
<tu tuid="267">
<prop type="lengthRatio">1.2777777777777777</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccinating</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Eżempju: pertussis</seg>
</tuv>
</tu>
<tu tuid="268">
<prop type="lengthRatio">0.8488372093023255</prop>
<tuv xml:lang="en">
<seg>It can cause severe spasms of cough and usually lasts three to six weeks.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tista' tikkawża spażmi severi ta' sogħla u normalment iddum bejn tliet u sitt ġimgħat.</seg>
</tuv>
</tu>
<tu tuid="269">
<prop type="lengthRatio">0.7654320987654321</prop>
<tuv xml:lang="en">
<seg>Pertussis (whooping cough) is a disease affecting the airways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis (is-sogħla konvulżiva) hija marda li taffettwa l-pajpijiet tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="270">
<prop type="lengthRatio">0.5625</prop>
<tuv xml:lang="en">
<seg>For more information, see measles factsheet .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għaldaqstant, il-benefiċċji fit-tul tat-tilqim jaf ma jkunux evidenti mal-ewwel.</seg>
</tuv>
</tu>
<tu tuid="271">
<prop type="lengthRatio">0.831081081081081</prop>
<tuv xml:lang="en">
<seg>Unlike a treatment given to cure an illness, vaccines are usually given to healthy people to prevent them from getting ill.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>B'mod differenti għal kura li tingħata biex tikkura marda, il-vaċċini normalment jingħataw lill-persuni b'saħħithom bħala prevenzjoni kontra l-mard.</seg>
</tuv>
</tu>
<tu tuid="272">
<prop type="lengthRatio">1.0072463768115942</prop>
<tuv xml:lang="en">
<seg>Many infectious diseases are very rare today thanks to vaccination, so the negative consequences of these diseases are sometimes forgotten.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħafna mard infettiv huwa rari ħafna illum il-ġurnata grazzi għat-tilqim, allura xi drabi l-konsegwenzi negattivi ta' dan il-mard jintesew.</seg>
</tuv>
</tu>
<tu tuid="273">
<prop type="lengthRatio">0.9690721649484536</prop>
<tuv xml:lang="en">
<seg>If people stopped being vaccinated, many of these diseases and related outbreaks could return.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jekk in-nies jieqfu jitlaqqmu, ħafna minn dan il-mard u t-tifqigħat relatati jistgħu jirritornaw.</seg>
</tuv>
</tu>
<tu tuid="274">
<prop type="lengthRatio">0.9130434782608695</prop>
<tuv xml:lang="en">
<seg>Vaccines are used in hundreds of millions of people worldwide each year to protect from serious diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini jintużaw kull sena fuq mijiet ta' miljuni ta' persuni madwar id-dinja biex jipproteġu kontra mard serju.</seg>
</tuv>
</tu>
<tu tuid="275">
<prop type="lengthRatio">0.9151515151515152</prop>
<tuv xml:lang="en">
<seg>The ECDC Surveillance Atlas of Infectious Diseases also provides data on other vaccine-preventable diseases, such as diphtheria, pertussis and rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Atlas tal-ECDC għas-Sorveljanza tal-Mard Infettiv jipprovdi wkoll data dwar mard ieħor li jista' jiġi evitat bil-vaċċini, bħad-difterite, il-pertussis u r-rubella.</seg>
</tuv>
</tu>
<tu tuid="276">
<prop type="lengthRatio">1.1111111111111112</prop>
<tuv xml:lang="en">
<seg>Situation of measles in the EU</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sitwazzjoni tal-ħosba fl-UE</seg>
</tuv>
</tu>
<tu tuid="277">
<prop type="lengthRatio">0.8285714285714286</prop>
<tuv xml:lang="en">
<seg>The data is based on information submitted and verified by Member States through ECDC's disease surveillance system.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Id-data hija bbażata fuq l-informazzjoni sottomessa u vverifikata mill-Istati Membri permezz tas-sistema tal-ECDC għas-sorveljanza tal-mard.</seg>
</tuv>
</tu>
<tu tuid="278">
<prop type="lengthRatio">0.7983870967741935</prop>
<tuv xml:lang="en">
<seg>It provides options for the user to filter information by criteria such as disease and time-period.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jipprovdi għażliet sabiex l-utent ikun jista' jiffiltra l-informazzjoni skont il-kriterji bħall-marda u l-perjodu ta' żmien.</seg>
</tuv>
</tu>
<tu tuid="279">
<prop type="lengthRatio">1.1785714285714286</prop>
<tuv xml:lang="en">
<seg>Catch-up vaccination and boosters</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tilqim ta' rkupru u boosters</seg>
</tuv>
</tu>
<tu tuid="280">
<prop type="lengthRatio">1.0683229813664596</prop>
<tuv xml:lang="en">
<seg>If a person does not know if they have been vaccinated against a certain disease they can usually get an extra dose without increasing the risk of serious side effects (1).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jekk persuna ma tkunx taf jekk ġietx imlaqqma kontra ċerta marda, normalment tista' tieħu doża żejda mingħajr ma żżid ir-riskju ta' effetti sekondarji serji (1).</seg>
</tuv>
</tu>
<tu tuid="281">
<prop type="lengthRatio">0.8896551724137931</prop>
<tuv xml:lang="en">
<seg>For some diseases, such as varicella (chickenpox) and rubella, it is also possible to do a test to check if the person is immune.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal xi mard, bħall-variċella (il-ġidri r-riħ) u r-rubella, huwa wkoll possibbli li jsir test biex jiġi vverifikat jekk il-persuna hijiex immuni.</seg>
</tuv>
</tu>
<tu tuid="282">
<prop type="lengthRatio">0.90625</prop>
<tuv xml:lang="en">
<seg>Some countries recommend booster doses at regular intervals during adolescence and adulthood, in order to maintain immunity over a longer period of time, against for example:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi pajjiżi jirrakkomandaw dożi booster f'intervalli regolari matul l-adoloxxenza u l-perjodu meta wieħed ikun adult, sabiex tinżamm l-immunità matul perjodu itwal ta' żmien, pereżempju kontra:</seg>
</tuv>
</tu>
<tu tuid="283">
<prop type="lengthRatio">0.7843137254901961</prop>
<tuv xml:lang="en">
<seg>Most vaccines provide lifelong immunity.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ħafna mill-vaċċini jipprovdu immunità tul il-ħajja.</seg>
</tuv>
</tu>
<tu tuid="284">
<prop type="lengthRatio">0.9716312056737588</prop>
<tuv xml:lang="en">
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pereżempju, minħabba n-numru li qed jiżdied ta' każijiet ta' ħosba fost l-adolexxenti u l-adulti żgħar, jeżistu programmi ta' rkupru f'numru ta' pajjiżi tal-UE/taż-ŻEE għal persuni li setgħu tilfu t-tilqim tal-ħosba meta kienu iżgħar jew li huma kbar wisq biex jirċevuha bħala tfal.</seg>
</tuv>
</tu>
<tu tuid="285">
<prop type="lengthRatio">0.9487179487179487</prop>
<tuv xml:lang="en">
<seg>Everyone should check if they have had the nationally recommended vaccinations, and consult a medical professional in case any catch-ups are needed.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kulħadd għandu jiċċekkja jekk kienx ħa t-tilqim rakkomandat b'mod nazzjonali, u jikkonsulta professjonist mediku f'każ li jkollu bżonn xi tilqim ta' rkupru.</seg>
</tuv>
</tu>
<tu tuid="286">
<prop type="lengthRatio">0.4166666666666667</prop>
<tuv xml:lang="en">
<seg>diphtheria</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xorta jistgħu jirkupraw.</seg>
</tuv>
</tu>
<tu tuid="287">
<prop type="lengthRatio">0.9393939393939394</prop>
<tuv xml:lang="en">
<seg>However, some vaccines provide immunity that decreases over time, known as ‘waning immunity'.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, xi vaċċini jipprovdu immunità li tonqos maż-żmien, magħrufa bħala "immunità li tbatti".</seg>
</tuv>
</tu>
<tu tuid="288">
<prop type="lengthRatio">0.922077922077922</prop>
<tuv xml:lang="en">
<seg>Catch-up vaccination programmes for specific diseases may be organised.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jistgħu jiġu organizzati programmi ta' tilqim ta' rkupru għal mard speċifiku.</seg>
</tuv>
</tu>
<tu tuid="289">
<prop type="lengthRatio">1.1866666666666668</prop>
<tuv xml:lang="en">
<seg>Some people may have missed a vaccination or did not get the recommended number of doses.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi persuni setgħu tilfu tilqima jew ma ħadux in-numru rakkomandat ta' dożi.</seg>
</tuv>
</tu>
<tu tuid="290">
<prop type="lengthRatio">1.0077519379844961</prop>
<tuv xml:lang="en">
<seg>Read more: https://ec.europa.eu/health/vaccination/overview_en and https://ec.europa.eu/info/departments/health-and-food-safety_en</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aqra aktar: https://ec.europa.eu/health/vaccination/overview_mt u https://ec.europa.eu/info/departments/health-and-food-safety_mt</seg>
</tuv>
</tu>
<tu tuid="291">
<prop type="lengthRatio">0.9649122807017544</prop>
<tuv xml:lang="en">
<seg>For more information visit: https://www.ema.europa.eu /</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni żur: https://www.ema.europa.eu /</seg>
</tuv>
</tu>
<tu tuid="292">
<prop type="lengthRatio">0.9649122807017544</prop>
<tuv xml:lang="en">
<seg>For more information visit: https://www.ecdc.europa.eu/</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni żur: https://www.ecdc.europa.eu/</seg>
</tuv>
</tu>
<tu tuid="293">
<prop type="lengthRatio">0.8739495798319328</prop>
<tuv xml:lang="en">
<seg>Communication and scientific experts in these organisations are involved in developing the contents (1).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-esperti ta' komunikazzjoni u dawk xjentifiċi f'dawn l-organizzazzjonijiet huma involuti fl-iżvilupp tal-kontenut (1).</seg>
</tuv>
</tu>
<tu tuid="294">
<prop type="lengthRatio">0.8255451713395638</prop>
<tuv xml:lang="en">
<seg>The core functions cover a wide spectrum of activities: surveillance, epidemic intelligence, response, scientific advice, microbiology, preparedness, public health training, international relations, health communication, and the scientific journal Eurosurveillance.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-funzjonijiet ewlenin ikopru spettru wiesa' ta' attivitajiet: is-sorveljanza, l-informazzjoni dwar l-epidemiji, ir-rispons, il-parir xjentifiku, il-mikrobijoloġija, it-tħejjija, it-taħriġ dwar is-saħħa pubblika, ir-relazzjonijiet internazzjonali, il-komunikazzjoni dwar is-saħħa, u l-ġurnal xjentifiku Eurosurveillance.</seg>
</tuv>
</tu>
<tu tuid="295">
<prop type="lengthRatio">0.8743169398907104</prop>
<tuv xml:lang="en">
<seg>EMA and its scientific committees examine all available data and assess their benefits and risks before they are approved and while they are marketed in the EU.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA u l-kumitati xjentifiċi tagħha jeżaminaw id-data kollha disponibbli u jivvalutaw il-benefiċċji u r-riskji tagħhom qabel ma jiġu approvati u waqt li jiġu kkummerċjalizzati fl-UE.</seg>
</tuv>
</tu>
<tu tuid="296">
<prop type="lengthRatio">0.9356435643564357</prop>
<tuv xml:lang="en">
<seg>The European Medicines Agency (EMA) is a decentralized agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Aġenzija Ewropea għall-Mediċini (EMA) hija aġenzija deċentralizzata tal-Unjoni Ewropea (UE) responsabbli għall-evalwazzjoni xjentifika, is-superviżjoni u l-monitoraġġ tas-sikurezza tal-mediċini fl-UE.</seg>
</tuv>
</tu>
<tu tuid="297">
<prop type="lengthRatio">0.967741935483871</prop>
<tuv xml:lang="en">
<seg>To improve vaccination uptake, the Council adopted a Recommendation to strengthen the EU cooperation on vaccine-preventable diseases in December 2018.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Biex itejjeb it-teħid tat-tilqim, f'Diċembru 2018 il-Kunsill adotta Rakkomandazzjoni dwar kooperazzjoni msaħħa tal-UE kontra l-mard li jista' jiġi evitat .</seg>
</tuv>
</tu>
<tu tuid="298">
<prop type="lengthRatio">0.9396984924623115</prop>
<tuv xml:lang="en">
<seg>It is an initiative of the European Union and was developed following the Council Recommendation on Strengthened Cooperation against Vaccine Preventable Diseases adopted in December 2018.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan huwa inizjattiva tal-Unjoni Ewropea u ġie żviluppat wara r- Rakkomandazzjoni tal-Kunsill dwar kooperazzjoni msaħħa kontra l-mard li jista' jiġi evitat bit-tilqim li ġiet adottata f'Diċembru 2018.</seg>
</tuv>
</tu>
<tu tuid="299">
<prop type="lengthRatio">0.9764705882352941</prop>
<tuv xml:lang="en">
<seg>The Commission is divided into departments that develop policies in specific areas.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Kummissjoni hija maqsuma f'dipartimenti li jiżviluppaw politiki f'oqsma speċifiċi.</seg>
</tuv>
</tu>
<tu tuid="300">
<prop type="lengthRatio">0.8294314381270903</prop>
<tuv xml:lang="en">
<seg>In the area of vaccine-preventable diseases, ECDC provides regular surveillance data, e.g. the number of confirmed cases, and scientific advice on vaccines, monitors disease outbreaks and develops materials to support communication on immunisation.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fil-qasam tal-mard li jista' jiġi evitat bil-vaċċini, l-ECDC jipprovdi data regolari dwar is-sorveljanza, eż. l-għadd ta' każijiet ikkonfermati, u parir xjentifiku dwar il-vaċċini, jimmonitorja t-tifqigħat tal-mard u jiżviluppa materjali biex tiġi appoġġjata l-komunikazzjoni dwar l-immunizzazzjoni.</seg>
</tuv>
</tu>
<tu tuid="301">
<prop type="lengthRatio">0.9252336448598131</prop>
<tuv xml:lang="en">
<seg>(1) The European Commission, ECDC and EMA have mechanisms in place in order to ensure impartiality.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(1) Il-Kummissjoni Ewropea, l-ECDC u l-EMA għandhom mekkaniżmi fis-seħħ sabiex tiġi żgurata l-imparzjalità.</seg>
</tuv>
</tu>
<tu tuid="302">
<prop type="lengthRatio">0.7884615384615384</prop>
<tuv xml:lang="en">
<seg>One of the departments is DG for Health and Food Safety , responsible for EU policy on food safety and health and for monitoring the implementation of related laws.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Wieħed mid-dipartimenti huwa d- DĠ għas-Saħħa u s-Sikurezza Alimentari , responsabbli għall-politika tal-UE dwar is-saħħa u s-sikurezza alimentari u biex jimmonitorja l-implimentazzjoni ta' liġijiet relatati.</seg>
</tuv>
</tu>
<tu tuid="303">
<prop type="lengthRatio">0.7653061224489796</prop>
<tuv xml:lang="en">
<seg>Representatives from EU and EEA countries' public health organisations were consulted for finalising the website's contents and its language versions.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Rappreżentanti mill-organizzazzjonijiet tas-saħħa pubblika tal-pajjiżi tal-UE u taż-ŻEE ġew ikkonsultati biex jiġi ffinalizzat il-kontenut tas-sit web kif ukoll il-verżjonijiet lingwistiċi tiegħu.</seg>
</tuv>
</tu>
<tu tuid="304">
<prop type="lengthRatio">0.9571428571428572</prop>
<tuv xml:lang="en">
<seg>ECDC also maintains the Vaccine Scheduler , an online, interactive platform showing the vaccination schedules of all EU Member States.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ECDC iżomm ukoll Skeda tal-Vaċċini , li hija pjattaforma online u interattiva li turi l-iskedi tat-tilqim tal-Istati Membri kollha tal-UE.</seg>
</tuv>
</tu>
<tu tuid="305">
<prop type="lengthRatio">0.8010471204188482</prop>
<tuv xml:lang="en">
<seg>Staff and experts are required to declare any personal interest or any interest in any business or organisation that could compromise their impartiality.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-persunal u l-esperti huma meħtieġa jiddikjaraw kwalunkwe interess personali jew kwalunkwe interess fi kwalunkwe negozju jew organizzazzjoni li jista' jikkomprometti l-imparzjalità tagħhom.</seg>
</tuv>
</tu>
<tu tuid="306">
<prop type="lengthRatio">0.9004329004329005</prop>
<tuv xml:lang="en">
<seg>This is to ensure that staff and experts do not, in the performance of their duties, deal with matters in which they may, directly or indirectly, have a personal interest that could impair their independence.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan bil-għan li jiġi żgurat li, meta jwettqu l-kompiti tagħhom, il-persunal u l-esperti ma jindirizzawx kwistjonijiet li jista' jkollhom interess personali fihom, b'mod dirett jew indirett, li jista' jxekkel l-indipendenza tagħhom.</seg>
</tuv>
</tu>
<tu tuid="307">
<prop type="lengthRatio">0.7590361445783133</prop>
<tuv xml:lang="en">
<seg>The initiative aims to tackle vaccine hesitancy, improve coordination on vaccine procurement, support research and innovation, and strengthen EU cooperation on vaccine-preventable diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-għan tal-inizjattiva huwa li tindirizza l-eżitazzjoni għall-vaċċini, ittejjeb il-koordinazzjoni dwar l-akkwist tal-vaċċini, tappoġġja r-riċerka u l-innovazzjoni, u ssaħħaħ il-kooperazzjoni tal-UE b'rabta mal-mard li jista' jiġi evitat bil-vaċċini.</seg>
</tuv>
</tu>
<tu tuid="308">
<prop type="lengthRatio">0.9348659003831418</prop>
<tuv xml:lang="en">
<seg>This website was developed by the European Centre for Disease Prevention and Control (ECDC), in partnership with the European Commission, specifically, its Department on Health and Food Safety (DG SANTE) and the European Medicines Agency (EMA).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan is-sit web ġie żviluppat miċ-Ċentru Ewropew għall-Prevenzjoni u l-Kontroll tal-Mard (ECDC), bi sħubija mal-Kummissjoni Ewropea, speċifikament, mad-Dipartiment għas-Saħħa u s-Sikurezza Alimentari (DĠ SANTE) tagħha u mal-Aġenzija Ewropea għall-Mediċini (EMA).</seg>
</tuv>
</tu>
<tu tuid="309">
<prop type="lengthRatio">0.890625</prop>
<tuv xml:lang="en">
<seg>EMA ensures the efficacy, quality and safety of vaccines.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA tiżgura l-effikaċja, il-kwalità u s-sikurezza tal-vaċċini.</seg>
</tuv>
</tu>
<tu tuid="310">
<prop type="lengthRatio">0.9135802469135802</prop>
<tuv xml:lang="en">
<seg>The European Commission is the EU's politically independent executive arm.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Kummissjoni Ewropea hija l-fergħa eżekuttiva politikament independenti tal-UE.</seg>
</tuv>
</tu>
<tu tuid="311">
<prop type="lengthRatio">0.9619047619047619</prop>
<tuv xml:lang="en">
<seg>ECDC is an EU scientific agency aimed at strengthening Europe's defences against infectious diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ECDC huwa aġenzija xjentifika tal-UE bil-għan li jissaħħu d-difiżi tal-Ewropa kontra mard li jittieħed.</seg>
</tuv>
</tu>
<tu tuid="312">
<prop type="lengthRatio">0.9609375</prop>
<tuv xml:lang="en">
<seg>EMA works closely with European and international partners and shares information on vaccines and good regulatory practice.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA taħdem mill-qrib mas-sħab Ewropej u internazzjonali u taqsam informazzjoni dwar il-vaċċini u l-prattika regolatorja tajba.</seg>
</tuv>
</tu>
<tu tuid="313">
<prop type="lengthRatio">2.272727272727273</prop>
<tuv xml:lang="en">
<seg>European Centre for Disease Prevention and Control</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Kummissjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="314">
<prop type="lengthRatio">0.8305084745762712</prop>
<tuv xml:lang="en">
<seg>EMA is a networking organisation whose activities involve thousands of experts from across Europe.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA hija organizzazzjoni ta' netwerking li l-attivitajiet tagħha jinvolvu lil eluf ta' esperti minn madwar l-Ewropa.</seg>
</tuv>
</tu>
<tu tuid="315">
<prop type="lengthRatio">1.0443037974683544</prop>
<tuv xml:lang="en">
<seg>It is alone responsible for drawing up proposals for new European legislation, and it implements the decisions of the European Parliament and the Council of the EU .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Waħedha hija responsabbli biex tfassal proposti għal leġiżlazzjoni Ewropea ġdida, u timplimenta d-deċiżjonijiet tal- Parlament Ewropew u tal- Kunsill tal-UE .</seg>
</tuv>
</tu>
<tu tuid="316">
<prop type="lengthRatio">0.9130434782608695</prop>
<tuv xml:lang="en">
<seg>non-productive cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>sogħla mhux produttiva.</seg>
</tuv>
</tu>
<tu tuid="317">
<prop type="lengthRatio">1.5</prop>
<tuv xml:lang="en">
<seg>More factsheets</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Influwenza</seg>
</tuv>
</tu>
<tu tuid="318">
<prop type="lengthRatio">0.9466666666666667</prop>
<tuv xml:lang="en">
<seg>The 2009 A(H1N1)pdm09 influenza pandemic accounted for 123 000 to 203 000 deaths worldwide and a significant global socio-economic burden (3).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pandemija tal-influwenza 2009 A(H1N1)pdm09 ammontat għal bejn 123 000 u 203 000 mewta madwar id-dinja u piż soċjoekonomiku globali sinifikanti (3).</seg>
</tuv>
</tu>
<tu tuid="319">
<prop type="lengthRatio">0.9734513274336283</prop>
<tuv xml:lang="en">
<seg>The mortality rate due to influenza has been estimated in the EU/EEA countries participating to the EuroMOMO network (1) to be as high as 25 deaths per 100 000 population in the 2016/27 and 2017/18 influenza seasons (2).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-rata ta' mortalità minħabba l-influwenza ġiet stmata fil-pajjiżi tal-UE/taż-ŻEE li pparteċipaw fin-netwerk EuroMOMO (1) bħala li laħqet sa 25 mewta għal kull 100 000 persuna fl-istaġuni tal-influwenza 2016/17 u 2017/18 (2).</seg>
</tuv>
</tu>
<tu tuid="320">
<prop type="lengthRatio">0.6363636363636364</prop>
<tuv xml:lang="en">
<seg>Who is at risk of influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Min qiegħed f'riskju li taqbdu l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="321">
<prop type="lengthRatio">0.9626865671641791</prop>
<tuv xml:lang="en">
<seg>Approximately 20% of the population gets infected with influenza each year and one in four infected people will develop symptoms.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madwar 20 % tal-popolazzjoni tiġi infettata bl-influwenza kull sena u waħda minn kull erba' persuni infettati se tiżviluppa s-sintomi.</seg>
</tuv>
</tu>
<tu tuid="322">
<prop type="lengthRatio">0.9473684210526315</prop>
<tuv xml:lang="en">
<seg>Complications of influenza include pneumonia and encephalitis (inflammation of the brain).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kumplikazzjonijiet tal-influwenza jinkludu pnewmonja u enċefalite (infjammazzjoni tal-moħħ).</seg>
</tuv>
</tu>
<tu tuid="323">
<prop type="lengthRatio">0.9864864864864865</prop>
<tuv xml:lang="en">
<seg>A pandemic is the rapid spread of a new human influenza around the world.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pandemija hija t-tixrid rapidu ta' influwenza umana ġdida madwar id-dinja.</seg>
</tuv>
</tu>
<tu tuid="324">
<prop type="lengthRatio">0.9625</prop>
<tuv xml:lang="en">
<seg>In Europe, influenza occurs in regular annual epidemics in the winter season.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Fl-Ewropa, l-influwenza sseħħ f'epidemiji annwali regolari fl-istaġun tax-xitwa.</seg>
</tuv>
</tu>
<tu tuid="325">
<prop type="lengthRatio">0.8401360544217688</prop>
<tuv xml:lang="en">
<seg>The EU Member States recommend seasonal influenza vaccination for risk groups, such as the elderly, as well as individuals with chronic medical conditions like heart disease, problems with the lungs and airways, diabetes or immune system problems.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Istati Membri tal-UE jirrakkomandaw tilqim kontra l-influwenza staġunali għall-gruppi li jinsabu f'riskju, bħall-anzjani, kif ukoll l-individwi b'kundizzjonijiet mediċi kroniċi bħal mard tal-qalb, problemi bil-pulmun u bil-pajpijiet tan-nifs, id-dijabete jew problemi bis-sistema immunitarja.</seg>
</tuv>
</tu>
<tu tuid="326">
<prop type="lengthRatio">0.9906103286384976</prop>
<tuv xml:lang="en">
<seg>In addition to vaccination, antiviral medicines have been shown to be safe and effective measures to prevent influenza infection or to reduce the severity of infection in certain settings, such as nursing homes.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Minbarra t-tilqim, il-mediċini antivirali ntwerew li huma miżuri siguri u effettivi biex tiġi evitata l-infezzjoni tal-influwenza jew biex titnaqqas is-severità tal-infezzjoni f'ċerti ambjenti, bħad-djar tal-kura.</seg>
</tuv>
</tu>
<tu tuid="327">
<prop type="lengthRatio">0.8805970149253731</prop>
<tuv xml:lang="en">
<seg>Vaccination is the most effective way to prevent influenza.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim huwa l-aktar mod effettiv biex tiġi evitata l-influwenza.</seg>
</tuv>
</tu>
<tu tuid="328">
<prop type="lengthRatio">0.775</prop>
<tuv xml:lang="en">
<seg>How can influenza be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="329">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>sore throat;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>uġigħ ta' ras;</seg>
</tuv>
</tu>
<tu tuid="330">
<prop type="lengthRatio">1.0294117647058822</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma s-sintomi tal-influwenza?</seg>
</tuv>
</tu>
<tu tuid="331">
<prop type="lengthRatio">0.4888888888888889</prop>
<tuv xml:lang="en">
<seg>(3) Simonsen L. et al.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal dawk li iva, is-sintomi komuni jinkludu:</seg>
</tuv>
</tu>
<tu tuid="332">
<prop type="lengthRatio">0.9</prop>
<tuv xml:lang="en">
<seg>What is influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="333">
<prop type="lengthRatio">0.8831168831168831</prop>
<tuv xml:lang="en">
<seg>Not everyone who is infected with an influenza virus becomes unwell.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Mhux kulħadd li jkun infettat b'virus tal-influwenza jibda jħossu ma jiflaħx.</seg>
</tuv>
</tu>
<tu tuid="334">
<prop type="lengthRatio">0.9279279279279279</prop>
<tuv xml:lang="en">
<seg>In addition to seasonal epidemics, novel influenza viruses may occasionally emerge and cause pandemics.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Minbarra l-epidemiji staġunali, xi drabi jistgħu jitfaċċaw viruses ta' influwenza ġodda li jikkawżaw pandemiji.</seg>
</tuv>
</tu>
<tu tuid="335">
<prop type="lengthRatio">0.7052238805970149</prop>
<tuv xml:lang="en">
<seg>For most cases of influenza, patients are advised to take bed rest and drink plenty of fluids in order to manage their symptoms; staying at home also minimises the risk of infecting others.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-biċċa l-kbira tal-każijiet ta' influwenza, il-pazjenti jingħataw il-parir biex joqogħdu fis-sodda u jistrieħu filwaqt li jixorbu ħafna fluwidi sabiex jikkontrollaw is-sintomi tagħhom; il-fatt li persuna toqgħod id-dar inaqqas ir-riskju li tinfetta lil ħaddieħor.</seg>
</tuv>
</tu>
<tu tuid="336">
<prop type="lengthRatio">0.9396551724137931</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-Organizzazzjoni Dinjija tas-Saħħa (WHO) tirrakkomanda wkoll it-tilqim għall-ħaddiema fil-qasam tal-kura tas-saħħa.</seg>
</tuv>
</tu>
<tu tuid="337">
<prop type="lengthRatio">0.7581395348837209</prop>
<tuv xml:lang="en">
<seg>Most EU Member States follow the WHO recommendations to vaccinate pregnant women, and some follow recommendations to vaccinate healthy children aged 6 - 59 months.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-biċċa l-kbira tal-Istati Membri tal-UE jsegwu r-rakkomandazzjonijiet tad-WHO għat-tilqim tan-nisa tqal, u xi wħud isegwu r-rakkomandazzjonijiet għat-tilqim ta' tfal b'saħħithom li għandhom bejn 6 xhur u 59 xahar.</seg>
</tuv>
</tu>
<tu tuid="338">
<prop type="lengthRatio">1.0384615384615385</prop>
<tuv xml:lang="en">
<seg>Children are infected slightly more often than adults.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tfal jiġu infettati ftit aktar spiss mill-adulti.</seg>
</tuv>
</tu>
<tu tuid="339">
<prop type="lengthRatio">0.8698630136986302</prop>
<tuv xml:lang="en">
<seg>(1) EuroMOMO - European monitoring of excess mortality for public health action: http://www.euromomo.eu/methods/objectives.html</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-mediċini antivirali, meħuda malajr kemm jista' jkun wara li l-pazjent taqbdu l-marda, huma miżuri siguri u effettivi għall-kura tal-influwenza.</seg>
</tuv>
</tu>
<tu tuid="340">
<prop type="lengthRatio">1.0082644628099173</prop>
<tuv xml:lang="en">
<seg>Severe illness and complications are more common in very young infants, the frail elderly and certain medical risk groups.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Mard u kumplikazzjonijiet severi huma aktar komuni fi tfal żgħar ħafna, l-anzjani debboli u ċerti gruppi b'riskju mediku.</seg>
</tuv>
</tu>
<tu tuid="341">
<prop type="lengthRatio">0.5555555555555556</prop>
<tuv xml:lang="en">
<seg>How is influenza treated?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma l-kumplikazzjonijiet tal-influwenza?</seg>
</tuv>
</tu>
<tu tuid="342">
<prop type="lengthRatio">1.3083333333333333</prop>
<tuv xml:lang="en">
<seg>(2) Nielsen J. et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'xi każijiet, il-bnedmin jistgħu jiġu infettati mill-annimali, bħal fil-każijiet tal-influwenza tat-tjur u tal-ħnieżer.</seg>
</tuv>
</tu>
<tu tuid="343">
<prop type="lengthRatio">2.1052631578947367</prop>
<tuv xml:lang="en">
<seg>What are the complications of influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>uġigħ fil-griżmejn;</seg>
</tuv>
</tu>
<tu tuid="344">
<prop type="lengthRatio">0.7481481481481481</prop>
<tuv xml:lang="en">
<seg>An update of seasonal influenza vaccines is needed yearly, since influenza viruses constantly evolve.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull sena huwa meħtieġ aġġornament tat-tilqim kontra l-influwenza staġunali, peress li l-viruses tal-influwenza jevolvi b'mod kontinwu.</seg>
</tuv>
</tu>
<tu tuid="345">
<prop type="lengthRatio">0.8620689655172413</prop>
<tuv xml:lang="en">
<seg>In some cases patients develop bacterial complications following influenza infection and need to be treated with antibiotics.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'xi każijiet, il-pazjenti jiżviluppaw kumplikazzjonijiet batterjali wara infezzjoni tal-influwenza u jkollhom bżonn jiġu kkurati b'antibijotiċi.</seg>
</tuv>
</tu>
<tu tuid="346">
<prop type="lengthRatio">0.8255813953488372</prop>
<tuv xml:lang="en">
<seg>This is mainly via direct contact with secretions from infectious patients, such as droplets of fluid released when they cough or breathe out.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan iseħħ prinċipalment minħabba kuntatt dirett ma' sekrezzjonijiet minn pazjenti infettati, bħall-qtar żgħir ta' fluwidu li joħroġ meta jisogħlu jew jieħdu nifs 'il barra.</seg>
</tuv>
</tu>
<tu tuid="347">
<prop type="lengthRatio">0.7857142857142857</prop>
<tuv xml:lang="en">
<seg>Animals can also be infected with influenza.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-annimali jistgħu jiġu infettati wkoll mill-influwenza.</seg>
</tuv>
</tu>
<tu tuid="348">
<prop type="lengthRatio">0.8282828282828283</prop>
<tuv xml:lang="en">
<seg>In uncomplicated cases, symptoms resolve spontaneously within one week from onset.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>F'każijiet mhux ikkumplikati, is-sintomi jgħaddu b'mod spontanju fi żmien ġimgħa minn meta taqbdek.</seg>
</tuv>
</tu>
<tu tuid="349">
<prop type="lengthRatio">1.962962962962963</prop>
<tuv xml:lang="en">
<seg>Note: The information contained in this factsheet is intended for the purpose of general information and should not be used as a substitute for the individual expertise and judgement of a healthcare professional.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Huwa rrakkomandat li l-pazjenti jfittxu parir mediku jekk il-kundizzjoni tagħhom tkompli taqleb għall-agħar.</seg>
</tuv>
</tu>
<tu tuid="350">
<prop type="lengthRatio">1.0232558139534884</prop>
<tuv xml:lang="en">
<seg>It analyses many sources of data, including:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din tanalizza bosta sorsi ta' data, inkluż:</seg>
</tuv>
</tu>
<tu tuid="351">
<prop type="lengthRatio">0.8666666666666667</prop>
<tuv xml:lang="en">
<seg>information shared by other regulators.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>informazzjoni kondiviża minn regolaturi oħra.</seg>
</tuv>
</tu>
<tu tuid="352">
<prop type="lengthRatio">0.8666666666666667</prop>
<tuv xml:lang="en">
<seg>For more information, see:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni, ara:</seg>
</tuv>
</tu>
<tu tuid="353">
<prop type="lengthRatio">0.8695652173913043</prop>
<tuv xml:lang="en">
<seg>reports from patients, parents and healthcare professionals;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>rapporti minn pazjenti, ġenituri u professjonisti tal-kura tas-saħħa;</seg>
</tuv>
</tu>
<tu tuid="354">
<prop type="lengthRatio">0.8682926829268293</prop>
<tuv xml:lang="en">
<seg>Once a vaccine is approved for use, EU/EEA national authorities and the European Medicines Agency (EMA), continually monitor side effects in people who have received the vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ladarba vaċċin jiġi approvat għall-użu, l-awtoritajiet nazzjonali tal-UE/taż-ŻEE u l- Aġenzija Ewropea għall-Mediċini (EMA), jimmonitorjaw kontinwament l-effetti sekondarji fuq in-nies li rċevew il-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="355">
<prop type="lengthRatio">0.7142857142857143</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety &amp; reporting side effects</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Monitoraġġ tas-sikurezza tal-vaċċin u rappurtar ta' effetti sekondarji</seg>
</tuv>
</tu>
<tu tuid="356">
<prop type="lengthRatio">0.75</prop>
<tuv xml:lang="en">
<seg>Information on these reported suspected side effects is publicly available on the European database of suspected adverse drug reaction reports .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni dwar dawn l-effetti sekondarji suspettati rrapportati hija disponibbli għall-pubbliku fuq il- bażi tad-data Ewropea ta' rapporti dwar reazzjoni avversa għal mediċina suspettata .</seg>
</tuv>
</tu>
<tu tuid="357">
<prop type="lengthRatio">0.944954128440367</prop>
<tuv xml:lang="en">
<seg>The process of monitoring the safety and managing the risks of medicines is called ‘pharmacovigilance'.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-proċess tal-monitoraġġ tas-sikurezza u l-immaniġġjar tar-riskji tal-mediċini jissejjaħ "farmakoviġilanza".</seg>
</tuv>
</tu>
<tu tuid="358">
<prop type="lengthRatio">0.8042553191489362</prop>
<tuv xml:lang="en">
<seg>More information on how to report suspected side effects can be found in the prescribing information or package leaflet or the European database of suspected adverse drug reaction reports .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aktar informazzjoni dwar kif tirrapporta effetti sekondarji suspettati tinstab fl-informazzjoni tal-preskrizzjoni jew fil-fuljett ta' tagħrif jew fil- bażi tad-data Ewropea ta' rapporti dwar reazzjoni avversa għal mediċina suspettata .</seg>
</tuv>
</tu>
<tu tuid="359">
<prop type="lengthRatio">0.7475728155339806</prop>
<tuv xml:lang="en">
<seg>Patients, healthcare professionals and pharmaceutical companies should report all suspected side effects to their national medicines regulatory authority.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pazjenti, il-professjonisti fil-qasam tal-kura tas-saħħa u l-kumpaniji farmaċewtiċi għandhom jirrapportaw l-effetti sekondarji suspettati kollha lill-awtorità regolatorja tal-mediċini nazzjonali tagħhom.</seg>
</tuv>
</tu>
<tu tuid="360">
<prop type="lengthRatio">0.9316239316239316</prop>
<tuv xml:lang="en">
<seg>EMA carefully assesses suspected side effects to determine if there is a causal link with the vaccine or not.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA tanalizza bir-reqqa effetti sekondarji suspettati biex tiddetermina jekk hemmx rabta kawżali mal-vaċċin jew le.</seg>
</tuv>
</tu>
<tu tuid="361">
<prop type="lengthRatio">0.9</prop>
<tuv xml:lang="en">
<seg>When needed, EMA and the other European regulators take action.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta jkun meħtieġ, l-EMA u r-regolaturi Ewropej l-oħra jieħdu azzjoni.</seg>
</tuv>
</tu>
<tu tuid="362">
<prop type="lengthRatio">0.8105263157894737</prop>
<tuv xml:lang="en">
<seg>EMA checks new information on the safety of all vaccines available in Europe.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-EMA tiċċekkja informazzjoni ġdida dwar is-sikurezza tal-vaċċini kollha disponibbli fl-Ewropa.</seg>
</tuv>
</tu>
<tu tuid="363">
<prop type="lengthRatio">1.3541666666666667</prop>
<tuv xml:lang="en">
<seg>This helps to rule out the possibility that it was a coincidence or that it was caused by factors unrelated to the vaccine itself.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jiżgura li kwalunkwe riskju possibbli jiġi identifikat u mmaniġġjat malajr kemm jista' jkun.</seg>
</tuv>
</tu>
<tu tuid="364">
<prop type="lengthRatio">0.8155339805825242</prop>
<tuv xml:lang="en">
<seg>(4) US CDC Pink Book - Measles: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(4) Pink Book tas-CDC tal-Istati Uniti - Il-Ħosba: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html</seg>
</tuv>
</tu>
<tu tuid="365">
<prop type="lengthRatio">0.9371980676328503</prop>
<tuv xml:lang="en">
<seg>measles is highly contagious and 3 out of 10 people affected develop complications (4), which can include ear infection, diarrhoea, pneumonia and encephalitis (inflammation of the brain tissue);</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-ħosba tittieħed ħafna u 3 minn kull 10 persuni milquta jiżviluppaw kumplikazzjonijiet (4), li jistgħu jinkludu infezzjoni tal-widnejn, dijarea, pulmonite u enċefalite (infjammazzjoni tat-tessut tal-moħħ);</seg>
</tuv>
</tu>
<tu tuid="366">
<prop type="lengthRatio">0.9950248756218906</prop>
<tuv xml:lang="en">
<seg>This list with examples includes diseases for which vaccines are included in the national immunisation programmes, and/or are given to persons considered to be at a higher risk of getting the disease.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din il-lista b'eżempji tinkludi mard li t-tilqim tiegħu huwa inkluż fil-programmi nazzjonali tal-immunizzazzjoni, u/jew jingħata lil persuni li jitqiesu li jinsabu f'riskju ogħla li taqbadhom il-marda.</seg>
</tuv>
</tu>
<tu tuid="367">
<prop type="lengthRatio">0.8652173913043478</prop>
<tuv xml:lang="en">
<seg>almost 9 out of 10 babies born to mothers who had rubella in early pregnancy, will suffer from congenital rubella syndrome (with conditions such as deafness, cataracts and learning disabilities) (2);</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kważi 9 minn kull 10 trabi li jitwieldu minn ommijiet li kellhom ir-rubella fil-bidu tat-tqala, se jbatu minn sindrome ta' rubella konġenitali (b'kondizzjonijiet bħal nuqqas ta' smigħ, katarretti u diżabilitajiet fit-tagħlim) (2);</seg>
</tuv>
</tu>
<tu tuid="368">
<prop type="lengthRatio">1.073394495412844</prop>
<tuv xml:lang="en">
<seg>Vaccination protects individuals against diseases that could have serious consequences for their health, for example:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-individwi kontra mard li jista' jkollu konsegwenzi serji fuq saħħithom, pereżempju:</seg>
</tuv>
</tu>
<tu tuid="369">
<prop type="lengthRatio">0.8432835820895522</prop>
<tuv xml:lang="en">
<seg>(2) ECDC factsheet - Congenital Rubella Syndrome: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(2) Skeda informattiva tal-ECDC - Is-Sindrome ta' Rubella Konġenitali: https://www.ecdc.europa.eu/en/congenital-rubella-syndrome/facts</seg>
</tuv>
</tu>
<tu tuid="370">
<prop type="lengthRatio">0.8142292490118577</prop>
<tuv xml:lang="en">
<seg>meningococcal disease kills 1 in 10 people affected, even with prompt diagnosis and treatment, while problems including neurological or hearing impairment and amputation occur in up to 20% of survivors (3);</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-marda meningokokkali toqtol 1 minn kull 10 persuni milquta, anki b'dijanjożi u trattament mill-ewwel, filwaqt li problemi li jinkludu insuffiċjenza newroloġika jew fis-smigħ u qtugħ ta' parti tal-ġisem iseħħu f'sa 20 % ta' dawk li jibqgħu ħajjin (3);</seg>
</tuv>
</tu>
<tu tuid="371">
<prop type="lengthRatio">0.8494623655913979</prop>
<tuv xml:lang="en">
<seg>(1) ECDC factsheet - Diphtheria: https://www.ecdc.europa.eu/en/diphtheria/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(1) Skeda informattiva tal-ECDC - Id-Difterja: https://www.ecdc.europa.eu/en/diphtheria/facts</seg>
</tuv>
</tu>
<tu tuid="372">
<prop type="lengthRatio">0.8279569892473119</prop>
<tuv xml:lang="en">
<seg>(5) ECDC factsheet - Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(5) Skeda informattiva tal-ECDC - Il-Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="373">
<prop type="lengthRatio">0.9622641509433962</prop>
<tuv xml:lang="en">
<seg>Complications include pneumonia, encephalopathy (a disease of the brain), seizures and even death (5).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-kumplikazzjonijiet jinkludu pulmonite, enċefalopatija (marda tal-moħħ), aċċessjonijiet u anki mewt (5).</seg>
</tuv>
</tu>
<tu tuid="374">
<prop type="lengthRatio">0.8974358974358975</prop>
<tuv xml:lang="en">
<seg>(3) ECDC factsheet - Meningococcal disease: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(3) Skeda informattiva tal-ECDC - Marda meningokokkali: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet</seg>
</tuv>
</tu>
<tu tuid="375">
<prop type="lengthRatio">0.8705882352941177</prop>
<tuv xml:lang="en">
<seg>diphtheria kills 1 in every 10 people who get it, even with treatment (1);</seg>
</tuv>
<tuv xml:lang="mt">
<seg>id-difterja toqtol 1 minn kull 10 persuni li taqbadhom, anki jekk tiġi ttrattata (1);</seg>
</tuv>
</tu>
<tu tuid="376">
<prop type="lengthRatio">0.7383720930232558</prop>
<tuv xml:lang="en">
<seg>pertussis (whooping cough) can be particularly serious in infants, causing coughing spells that may recur for up to two months.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>il-pertussis (sogħla konvulżiva) tista' partikolarment tkun serja fit-tfal żgħar, u tikkawża episodji ta' ħin twil fejn wieħed jisgħol li jistgħu jerġgħu jseħħu sa xahrejn.</seg>
</tuv>
</tu>
<tu tuid="377">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>An example is aluminium;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Eżempju huwa l-aluminju;</seg>
</tuv>
</tu>
<tu tuid="378">
<prop type="lengthRatio">0.9408284023668639</prop>
<tuv xml:lang="en">
<seg>There may also be trace amounts of other substances used in the manufacturing process, such as ovalbumin (a protein found in eggs) or neomycin (an antibiotic).</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jista' jkun hemm ukoll traċċi ta' sustanzi oħra użati fil-proċess ta' manifattura, bħall-albumina tal-bajd (proteina li tinsab fil-bajd) jew in-neomiċina (antibijotiku).</seg>
</tuv>
</tu>
<tu tuid="379">
<prop type="lengthRatio">0.8053097345132744</prop>
<tuv xml:lang="en">
<seg>Regulators check that their benefits are weighed against the risk of any reactions to them.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-regolaturi jivverifikaw li l-benefiċċji tagħhom jiġu ppeżati kontra r-riskju ta' kwalunkwe reazzjoni għalihom.</seg>
</tuv>
</tu>
<tu tuid="380">
<prop type="lengthRatio">0.9345794392523364</prop>
<tuv xml:lang="en">
<seg>excipients: these are inactive ingredients, like water, or sodium chloride (salt), as well as the preservatives or stabilisers that help the vaccine remain unchanged during storage, keeping it active.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>eċċipjenti: dawn huma ingredjenti inattivi, bħall-ilma, jew il-klorur tas-sodju (melħ), kif ukoll il-preservattivi jew l-istabbilizzaturi li jgħinu lill-vaċċin jibqa' l-istess matul il-ħżin, u b'hekk jinżamm attiv.</seg>
</tuv>
</tu>
<tu tuid="381">
<prop type="lengthRatio">0.8819444444444444</prop>
<tuv xml:lang="en">
<seg>adjuvants: these improve the immune response to the vaccine by making the response stronger, faster and more sustained in time.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>aġġuvanti: dawn itejbu r-reazzjoni immuni għall-vaċċin billi eventwalment jagħmlu r-reazzjoni aktar b'saħħitha, aktar rapida u aktar prolungata.</seg>
</tuv>
</tu>
<tu tuid="382">
<prop type="lengthRatio">1.1666666666666667</prop>
<tuv xml:lang="en">
<seg>In addition to one or more antigens, there are other components in a vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Minbarra antiġene wieħed jew aktar, f'vaċċin hemm komponenti oħra.</seg>
</tuv>
</tu>
<tu tuid="383">
<prop type="lengthRatio">1.7073170731707317</prop>
<tuv xml:lang="en">
<seg>For example, the package leaflet will state if there are special precautions for use of a vaccine in people with certain allergies, such as vaccines including trace amounts of egg in people with an egg allergy.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn is-sustanzi jiġu kkontrollati b'mod konsistenti biex jiġi żgurat li jkunu preżenti f'livelli li ntwera li huma sikuri.</seg>
</tuv>
</tu>
<tu tuid="384">
<prop type="lengthRatio">0.8622448979591837</prop>
<tuv xml:lang="en">
<seg>For more information about national vaccination programmes, see the ECDC vaccine scheduler and visit the official websites on immunisation of the EU/EEA countries here .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni dwar il-programmi nazzjonali tat-tilqim, ara l- iskedatur tal-vaċċini tal-ECDC u żur is-siti web uffiċjali dwar l-immunizzazzjoni tal-pajjiżi tal-UE/taż-ŻEE minnhawnhekk .</seg>
</tuv>
</tu>
<tu tuid="385">
<prop type="lengthRatio">0.9468085106382979</prop>
<tuv xml:lang="en">
<seg>Some vaccines protect against only one disease, but others protect against more than one.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi vaċċini jipproteġu kontra marda waħda biss, iżda oħrajn jipproteġu kontra aktar minn waħda.</seg>
</tuv>
</tu>
<tu tuid="386">
<prop type="lengthRatio">0.8859649122807017</prop>
<tuv xml:lang="en">
<seg>Sometimes, more than one vaccine may be given at once to protect against several infectious diseases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi drabi, jista' jingħata aktar minn vaċċin wieħed fl-istess ħin biex jipproteġi kontra diversi mardiet infettivi.</seg>
</tuv>
</tu>
<tu tuid="387">
<prop type="lengthRatio">0.8262548262548263</prop>
<tuv xml:lang="en">
<seg>In addition, vaccines to protect against specific diseases are sometimes recommended for ‘high-risk' groups, such as people with long-term health conditions or people planning to travel to other parts of the world.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Barra minn hekk, il-vaċċini li jipproteġu kontra mard speċifiku xi drabi huma rakkomandati għal gruppi ta' "riskju għoli", bħal persuni b'kundizzjonijiet tas-saħħa għal perjodu twil ta' żmien jew persuni li beħsiebhom jivvjaġġaw lejn partijiet oħra tad-dinja.</seg>
</tuv>
</tu>
<tu tuid="388">
<prop type="lengthRatio">0.9647887323943662</prop>
<tuv xml:lang="en">
<seg>Most national vaccination programmes in the EU/EEA include vaccines for up to twenty diseases which are given to people at specific ages.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-biċċa l-kbira tal-programmi nazzjonali tat-tiqim fl-UE/fiż-ŻEE jinkludu vaċċini sa għoxrin marda li jingħataw lin-nies f'etajiet speċifiċi.</seg>
</tuv>
</tu>
<tu tuid="389">
<prop type="lengthRatio">0.896551724137931</prop>
<tuv xml:lang="en">
<seg>Combined use of vaccines is well established and based on scientific studies on its benefits and safety.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-użu kkombinat tal-vaċċini huwa stabbilit sew u bbażat fuq studji xjentifiċi dwar il-benefiċċji u s-sigurtà tiegħu.</seg>
</tuv>
</tu>
<tu tuid="390">
<prop type="lengthRatio">0.9245283018867925</prop>
<tuv xml:lang="en">
<seg>This is based on local conditions, such as how common the disease is, as well as economic factors.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan huwa bbażat fuq il-kundizzjonijiet lokali, bħal kemm hija komuni l-marda, kif ukoll fatturi ekonomiċi.</seg>
</tuv>
</tu>
<tu tuid="391">
<prop type="lengthRatio">0.8571428571428571</prop>
<tuv xml:lang="en">
<seg>Decisions on vaccines in use in different European countries</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Deċiżjonijiet dwar il-vaċċini li jintużaw f'pajjiżi Ewropej differenti</seg>
</tuv>
</tu>
<tu tuid="392">
<prop type="lengthRatio">0.890625</prop>
<tuv xml:lang="en">
<seg>Information and links to the VSN member websites is available here: https://www.vaccinesafetynet.org/vsn/network .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni u links għas-siti web tal-membri tal-VSN huma disponibbli hawnhekk: https://www.vaccinesafetynet.org/vsn/network .</seg>
</tuv>
</tu>
<tu tuid="393">
<prop type="lengthRatio">0.9736842105263158</prop>
<tuv xml:lang="en">
<seg>It usually occurs within minutes of exposure to the source of the allergy.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Normalment din isseħħ ftit minuti wara l-esponiment għas-sors tal-allerġija.</seg>
</tuv>
</tu>
<tu tuid="394">
<prop type="lengthRatio">1.4666666666666666</prop>
<tuv xml:lang="en">
<seg>For up-to-date information on COVID-19, see:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni, ara:</seg>
</tuv>
</tu>
<tu tuid="395">
<prop type="lengthRatio">0.8846153846153846</prop>
<tuv xml:lang="en">
<seg>The Vaccine Safety Net (VSN) is a global network of websites, established by the World Health Organization, that provides reliable information on vaccine safety.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-Vaccine Safety Net (VSN) hija netwerk globali ta' siti web, stabbiliti mill-Organizzazzjoni Dinjija tas-Saħħa, li tipprovdi informazzjoni affidabbli dwar is-sikurezza tal-vaċċini.</seg>
</tuv>
</tu>
<tu tuid="396">
<prop type="lengthRatio">0.9064516129032258</prop>
<tuv xml:lang="en">
<seg>Certain immune system disorders (e.g. congenital immune deficiencies), or medical treatments (e.g. chemotherapy, a bone marrow or other organ transplant, or high doses of steroids) are contraindications for some vaccines, such as measles, mumps, rubella, varicella or oral typhoid.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ċerti disturbi tas-sistema immunitarja (eż. disturbi immuni konġenitali), jew kuri mediċi (eż. kimoterapija, trapjant tal-mudullun jew ta' kwalunkwe organu ieħor, jew dożi għoljin ta' sterojdi) huma kontraindikazzjonijiet għal ċerti vaċċini, bħall-ħosba, il-gattone, ir-rubella, il-variċella jew tifojde orali.</seg>
</tuv>
</tu>
<tu tuid="397">
<prop type="lengthRatio">0.8363636363636363</prop>
<tuv xml:lang="en">
<seg>Rubella (German measles) is a viral infection.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Ir-rubella (il-ħosba Ġermaniża) hija infezzjoni virali.</seg>
</tuv>
</tu>
<tu tuid="398">
<prop type="lengthRatio">1.2083333333333333</prop>
<tuv xml:lang="en">
<seg>What are the symptoms of HPV?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif jiġi ttrattat l-HPV?</seg>
</tuv>
</tu>
<tu tuid="399">
<prop type="lengthRatio">0.8564102564102564</prop>
<tuv xml:lang="en">
<seg>Immunocompromised patients also benefit from those around them being fully vaccinated (such as family members, caregivers), as then they are also indirectly protected.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Pazjenti immunokompromessi jibbenefikaw ukoll mill-fatt li dawk ta' madwarhom ikunu tlaqqmu b'mod komplet (bħall-membri tal-familja, l-indokraturi), peress li b'mod indirett ikunu protetti wkoll.</seg>
</tuv>
</tu>
<tu tuid="400">
<prop type="lengthRatio">1.1791044776119404</prop>
<tuv xml:lang="en">
<seg>A vaccine's ability to prevent a specific disease determines its effectiveness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim huwa l-aktar mod effettiv biex tiġi evitata l-influwenza.</seg>
</tuv>
</tu>
<tu tuid="401">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>For more information about the network visit: https://vaccinesafetynet.org .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni dwar in-netwerk żur: https://vaccinesafetynet.org .</seg>
</tuv>
</tu>
<tu tuid="402">
<prop type="lengthRatio">0.8260869565217391</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV) infection is a viral infection that is mainly sexually transmitted by direct contact...</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-infezzjoni tal-virus tal-papilloma uman (HPV) hija infezzjoni virali li tiġi trażmessa l-aktar sesswalment permezz ta' kuntatt dirett...</seg>
</tuv>
</tu>
<tu tuid="403">
<prop type="lengthRatio">1.6583333333333334</prop>
<tuv xml:lang="en">
<seg>A vaccine may be contraindicated for certain people, meaning they should not receive it. Possible contraindications should be always discussed with the healthcare provider before receiving a vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kontraindikazzjonijiet possibbli għandhom dejjem jiġu diskussi mal-fornitur tal-kura tas-saħħa qabel ma jingħata vaċċin.</seg>
</tuv>
</tu>
<tu tuid="404">
<prop type="lengthRatio">0.7580645161290323</prop>
<tuv xml:lang="en">
<seg>For more information, see pertussis factsheet .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aktar skedi informattivi se jiġu inklużi fi stadju aktar tard.</seg>
</tuv>
</tu>
<tu tuid="405">
<prop type="lengthRatio">0.8958333333333334</prop>
<tuv xml:lang="en">
<seg>Official websites from EU and EEA countries</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Siti web uffiċjali mill-pajjiżi tal-UE u taż-ŻEE</seg>
</tuv>
</tu>
<tu tuid="406">
<prop type="lengthRatio">1.0256410256410255</prop>
<tuv xml:lang="en">
<seg>What are the complications of pertussis?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="407">
<prop type="lengthRatio">1.1627906976744187</prop>
<tuv xml:lang="en">
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Approvazzjoni tal-vaċċini fl-Unjoni Ewropea</seg>
</tuv>
</tu>
<tu tuid="408">
<prop type="lengthRatio">1.6936936936936937</prop>
<tuv xml:lang="en">
<seg>About 1 measles patient in 1 000 develops inflammation of the brain tissue (encephalitis), a condition that results in permanent neurological disability in approximately one of four cases.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Minbarra l-epidemiji staġunali, xi drabi jistgħu jitfaċċaw viruses ta' influwenza ġodda li jikkawżaw pandemiji.</seg>
</tuv>
</tu>
<tu tuid="409">
<prop type="lengthRatio">1.5961538461538463</prop>
<tuv xml:lang="en">
<seg>Pertussis is spread via airborne droplets produced when the infected person coughs.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tfal jiġu infettati ftit aktar spiss mill-adulti.</seg>
</tuv>
</tu>
<tu tuid="410">
<prop type="lengthRatio">0.8787878787878788</prop>
<tuv xml:lang="en">
<seg>How can measles be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta għandu jiġi evitat it-tilqim</seg>
</tuv>
</tu>
<tu tuid="411">
<prop type="lengthRatio">0.7352941176470589</prop>
<tuv xml:lang="en">
<seg>How can HPV be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-HPV, kif tista' tiġi pprevenuta?</seg>
</tuv>
</tu>
<tu tuid="412">
<prop type="lengthRatio">2.4375</prop>
<tuv xml:lang="en">
<seg>Benefits of vaccination for individuals</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Reazzjoni immuni</seg>
</tuv>
</tu>
<tu tuid="413">
<prop type="lengthRatio">1.5963302752293578</prop>
<tuv xml:lang="en">
<seg>Some countries recommend booster doses at regular intervals during adolescence and adulthood, in order to maintain immunity over a longer period of time, against for example:</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipproteġi lill-individwi kontra mard li jista' jkollu konsegwenzi serji fuq saħħithom, pereżempju:</seg>
</tuv>
</tu>
<tu tuid="414">
<prop type="lengthRatio">1.1666666666666667</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi kkurata l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="415">
<prop type="lengthRatio">1.0357142857142858</prop>
<tuv xml:lang="en">
<seg>Some vaccines are contraindicated during pregnancy, such as measles, mumps and rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xi vaċċini jkunu kontraindikati matul it-tqala, bħall-ħosba, il-gattone u r-rubella.</seg>
</tuv>
</tu>
<tu tuid="416">
<prop type="lengthRatio">1.608695652173913</prop>
<tuv xml:lang="en">
<seg>smallpox is now eradicated worldwide;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Tista' tinfirex malajr.</seg>
</tuv>
</tu>
<tu tuid="417">
<prop type="lengthRatio">0.8473282442748091</prop>
<tuv xml:lang="en">
<seg>There may be other contraindications for specific vaccines, which need discussing with the healthcare provider.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jista' jkun hemm kontraindikazzjonijiet oħra għal vaċċini speċifiċi, li jkunu jeħtieġu diskussjoni mal-fornitur tal-kura tas-saħħa.</seg>
</tuv>
</tu>
<tu tuid="418">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>previous contact with the disease;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>iż-żmien minn mindu jkunu tlaqqmu;</seg>
</tuv>
</tu>
<tu tuid="419">
<prop type="lengthRatio">0.8968253968253969</prop>
<tuv xml:lang="en">
<seg>Anaphylaxis is a rare, rapid, extreme allergic reaction which can cause shock, swelling and difficulty breathing.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-anafilassi hija reazzjoni allerġika estrema, mgħaġġla u rari li tista' tikkawża xokk, nefħa u diffikultà fit-teħid tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="420">
<prop type="lengthRatio">0.9171974522292994</prop>
<tuv xml:lang="en">
<seg>A history of 'anaphylactic' or other serious allergic reaction after receiving a vaccine is a contraindication to further doses of that vaccine.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Storja ta' reazzjoni "anafilattika" jew reazzjoni allerġika serja oħra wara li jkun ingħata vaċċin hija kontraindikazzjoni għal aktar dożi ta' dak il-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="421">
<prop type="lengthRatio">1.1311475409836065</prop>
<tuv xml:lang="en">
<seg>Smallpox is now eradicated worldwide in humans thanks to vaccination.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għall-protezzjoni massima huma meħtieġa żewġ dożi tal-vaċċin.</seg>
</tuv>
</tu>
<tu tuid="422">
<prop type="lengthRatio">2.1267605633802815</prop>
<tuv xml:lang="en">
<seg>The ECDC Surveillance Atlas of Infectious Diseases also provides data on other vaccine-preventable diseases, such as diphtheria, pertussis and rubella.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Għal aktar informazzjoni, ara l-iskeda informattiva dwar il-pertussis .</seg>
</tuv>
</tu>
<tu tuid="423">
<prop type="lengthRatio">0.8888888888888888</prop>
<tuv xml:lang="en">
<seg>What are the complications of influenza?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhuma l-kumplikazzjonijiet tal-influwenza?</seg>
</tuv>
</tu>
<tu tuid="424">
<prop type="lengthRatio">0.7986577181208053</prop>
<tuv xml:lang="en">
<seg>When looking at health-related information, it can be difficult to judge the quality and accuracy of information found.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Meta wieħed iħares lejn l-informazzjoni relatata mas-saħħa, jaf ikun diffiċli li wieħed jiġġudika l-kwalità u l-preċiżjoni tal-informazzjoni misjuba.</seg>
</tuv>
</tu>
<tu tuid="425">
<prop type="lengthRatio">0.8285714285714286</prop>
<tuv xml:lang="en">
<seg>How can rubella be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="426">
<prop type="lengthRatio">0.6595744680851063</prop>
<tuv xml:lang="en">
<seg>Twitter Facebook Linked In Mail</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Portal Ewropew ta 'Informazzjoni dwar it-Tilqim</seg>
</tuv>
</tu>
<tu tuid="427">
<prop type="lengthRatio">0.8580645161290322</prop>
<tuv xml:lang="en">
<seg>Vaccines are recommended for different age groups, often for infants and children, but also for teenagers, adults and elderly people.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċini huma rrakkomandati għal gruppi ta' etajiet differenti, ħafna drabi għat-trabi u t-tfal, iżda wkoll għall-adolexxenti, l-adulti u n-nies anzjani.</seg>
</tuv>
</tu>
<tu tuid="428">
<prop type="lengthRatio">0.9171597633136095</prop>
<tuv xml:lang="en">
<seg>The regulators can only approve the vaccine if its scientific evaluation of the tests results show that the vaccine's benefits are greater than its risks .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-awtoritajiet regolatorji tal-mediċini jistgħu jagħmlu spezzjonijiet biex jiżguraw li l-informazzjoni li jipprovdi l-iżviluppatur tal-vaċċin hija ta' min joqgħod fuqha.</seg>
</tuv>
</tu>
<tu tuid="429">
<prop type="lengthRatio">1.1111111111111112</prop>
<tuv xml:lang="en">
<seg>The vaccine developer tests the vaccine in three phases of clinical trials, with larger numbers of people in each phase.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Huwa rrakkomandat li l-pazjenti jfittxu parir mediku jekk il-kundizzjoni tagħhom tkompli taqleb għall-agħar.</seg>
</tuv>
</tu>
<tu tuid="430">
<prop type="lengthRatio">1.0434782608695652</prop>
<tuv xml:lang="en">
<seg>Community immunity occurs when enough people in a population are immune to an infectious disease</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Madankollu, in-nies ma jistgħux jiddependu fuq l-immunità komunitarja għal xi mard infettiv.</seg>
</tuv>
</tu>
<tu tuid="431">
<prop type="lengthRatio">0.88</prop>
<tuv xml:lang="en">
<seg>(3) Simonsen L. et al.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi kkurata l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="432">
<prop type="lengthRatio">2.3220338983050848</prop>
<tuv xml:lang="en">
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull min mhuwiex imlaqqam kontra l-ħosba jew li ma kellux il-marda jinsab f'riskju li taqbdu l-ħosba fi kwalunkwe età.</seg>
</tuv>
</tu>
<tu tuid="433">
<prop type="lengthRatio">2.176470588235294</prop>
<tuv xml:lang="en">
<seg>PLoS Med. 2013 Nov; 10(11): e1001558.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Antikorpi&amp;nbsp;3.</seg>
</tuv>
</tu>
<tu tuid="434">
<prop type="lengthRatio">0.9473684210526315</prop>
<tuv xml:lang="en">
<seg>Influenza is easily transmitted from person to person.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ħosba tinfirex faċilment fost individwi mhux imlaqqma.</seg>
</tuv>
</tu>
<tu tuid="435">
<prop type="lengthRatio">0.5066666666666667</prop>
<tuv xml:lang="en">
<seg>What are the complications of measles?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Liema huma l-effetti sekondarji l-aktar komuni fuq perjodu ta' żmien qasir?</seg>
</tuv>
</tu>
<tu tuid="436">
<prop type="lengthRatio">1.9156626506024097</prop>
<tuv xml:lang="en">
<seg>However, antibiotics are often used to treat complications with bacterial infections that can develop because of measles, such as pneumonia and ear infections.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn l-epidemiji huma assoċjati ma' rati għoljin ta' rikoveri l-isptar u mortalità.</seg>
</tuv>
</tu>
<tu tuid="437">
<prop type="lengthRatio">1.0104166666666667</prop>
<tuv xml:lang="en">
<seg>Pneumonia is a potential serious complication that has led to the death of some measles patients.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jiżgura li kwalunkwe riskju possibbli jiġi identifikat u mmaniġġjat malajr kemm jista' jkun.</seg>
</tuv>
</tu>
<tu tuid="438">
<prop type="lengthRatio">2.6166666666666667</prop>
<tuv xml:lang="en">
<seg>(2) Nielsen J. et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-ewwel tilqima ġiet żviluppata fis-seklu 18 fir-Renju Unit.</seg>
</tuv>
</tu>
<tu tuid="439">
<prop type="lengthRatio">0.7692307692307693</prop>
<tuv xml:lang="en">
<seg>They can include mild fever, or pain or redness at the injection site.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Din tiġi kkawżata minn batterji fil-ħalq, fl-imnieħer u fil-griżmejn ta' persuna infettata.</seg>
</tuv>
</tu>
<tu tuid="440">
<prop type="lengthRatio">1.5806451612903225</prop>
<tuv xml:lang="en">
<seg>EMA is a networking organisation whose activities involve thousands of experts from across Europe.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>L-influwenza hija trażmessa faċilment minn persuna għall-oħra.</seg>
</tuv>
</tu>
<tu tuid="441">
<prop type="lengthRatio">0.7330097087378641</prop>
<tuv xml:lang="en">
<seg>Healthcare professionals (e.g. doctors, nurses) have a role in ensuring that patients in their care receive the recommended vaccines at the right time.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pazjenti, il-professjonisti fil-qasam tal-kura tas-saħħa u l-kumpaniji farmaċewtiċi għandhom jirrapportaw l-effetti sekondarji suspettati kollha lill-awtorità regolatorja tal-mediċini nazzjonali tagħhom.</seg>
</tuv>
</tu>
<tu tuid="442">
<prop type="lengthRatio">1.8073394495412844</prop>
<tuv xml:lang="en">
<seg>A variety of measures are employed to avoid the further spread of measles, such as quarantine from school or work for both the ill person and those close contacts with uncertain vaccination status.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis fi trabi mhux imlaqqma jew trabi li ommhom ma kinitx imlaqqma tista' tkun partikolarment severa.</seg>
</tuv>
</tu>
<tu tuid="443">
<prop type="lengthRatio">2.054054054054054</prop>
<tuv xml:lang="en">
<seg>There are some differences in the way countries organise their vaccination schedules, which are similar but not identical in different EU/EEA countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn sempliċiment jikkunsidraw ċirkostanzi u sistemi tas-saħħa differenti.</seg>
</tuv>
</tu>
<tu tuid="444">
<prop type="lengthRatio">2.0833333333333335</prop>
<tuv xml:lang="en">
<seg>The most severe forms of pertussis are in infants.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xorta jistgħu jirkupraw.</seg>
</tuv>
</tu>
<tu tuid="445">
<prop type="lengthRatio">0.8865979381443299</prop>
<tuv xml:lang="en">
<seg>Below are links to official websites with information on vaccination from public health organisations of the European Union (EU) and European Economic Area (EEA) countries.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Hawn taħt hawn il-links għas-siti web uffiċjali b'informazzjoni dwar it-tilqim mill-organizzazzjonijiet tas-saħħa pubblika tal-pajjiżi tal-Unjoni Ewropea (UE) u taż-Żona Ekonomika Ewropea (ŻEE).</seg>
</tuv>
</tu>
<tu tuid="446">
<prop type="lengthRatio">1.1884057971014492</prop>
<tuv xml:lang="en">
<seg>In uncomplicated cases, symptoms resolve spontaneously within one week from onset.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tikka fin-nofs tirrappreżenta persuna waħda affettwata minn marda.</seg>
</tuv>
</tu>
<tu tuid="447">
<prop type="lengthRatio">2.0217391304347827</prop>
<tuv xml:lang="en">
<seg>The severity of the disease varies widely, from no symptoms at all through to severe illness.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Illum il-ġurnata, hemm tilqim għal ħafna mard.</seg>
</tuv>
</tu>
<tu tuid="448">
<prop type="lengthRatio">1.4415584415584415</prop>
<tuv xml:lang="en">
<seg>This may involve looking at vaccination records or the vaccination schedules in place when the person was born.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jistgħu jiġu organizzati programmi ta' tilqim ta' rkupru għal mard speċifiku.</seg>
</tuv>
</tu>
<tu tuid="449">
<prop type="lengthRatio">1.0833333333333333</prop>
<tuv xml:lang="en">
<seg>Mild reactions such as fever, redness or swelling at the injection site have been reported.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-ġidri, illum il-ġurnatanqerdet mid-dinja kollha fil-bnedmin bis-saħħa tat-tilqim.</seg>
</tuv>
</tu>
<tu tuid="450">
<prop type="lengthRatio">0.8924731182795699</prop>
<tuv xml:lang="en">
<seg>Vaccination can eliminate diseases or reduce the number of new cases significantly.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-pertussis hija marda batterika infettiva ħafna li tinvolvi l-pulmun u l-passaġġi tan-nifs.</seg>
</tuv>
</tu>
<tu tuid="451">
<prop type="lengthRatio">1.0416666666666667</prop>
<tuv xml:lang="en">
<seg>Source: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sors: Plotkin S, Orenstein W, Offit P. Vaccines.</seg>
</tuv>
</tu>
<tu tuid="452">
<prop type="lengthRatio">0.8666666666666667</prop>
<tuv xml:lang="en">
<seg>Human papillomavirus (HPV)</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Virus tal-papilloma uman (HPV)</seg>
</tuv>
</tu>
<tu tuid="453">
<prop type="lengthRatio">0.967741935483871</prop>
<tuv xml:lang="en">
<seg>For more information check the ECDC website: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
<tuv xml:lang="mt">
<seg>(5) Skeda informattiva tal-ECDC - Il-Pertussis: https://www.ecdc.europa.eu/en/pertussis/facts</seg>
</tuv>
</tu>
<tu tuid="454">
<prop type="lengthRatio">1.1578947368421053</prop>
<tuv xml:lang="en">
<seg>fever or feverishness;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>uġigħ fil-griżmejn;</seg>
</tuv>
</tu>
<tu tuid="455">
<prop type="lengthRatio">2.0833333333333335</prop>
<tuv xml:lang="en">
<seg>Monitoring vaccine safety &amp; reporting side effects</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Aktar skedi informattivi</seg>
</tuv>
</tu>
<tu tuid="456">
<prop type="lengthRatio">1.4666666666666666</prop>
<tuv xml:lang="en">
<seg>(3) Simonsen L. et al.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>X'inhi l-ħosba?</seg>
</tuv>
</tu>
<tu tuid="457">
<prop type="lengthRatio">1.4230769230769231</prop>
<tuv xml:lang="en">
<seg>smallpox is now eradicated worldwide;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tinfirex l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="458">
<prop type="lengthRatio">1.5161290322580645</prop>
<tuv xml:lang="en">
<seg>For more information, see pertussis factsheet .</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tiġi ttrattata l-pertussis?</seg>
</tuv>
</tu>
<tu tuid="459">
<prop type="lengthRatio">0.9545454545454546</prop>
<tuv xml:lang="en">
<seg>non-productive cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kif jiġi manifatturat.</seg>
</tuv>
</tu>
<tu tuid="460">
<prop type="lengthRatio">1.6666666666666667</prop>
<tuv xml:lang="en">
<seg>It is also known as whooping cough.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Il-vaċċin huwa sikur?</seg>
</tuv>
</tu>
<tu tuid="461">
<prop type="lengthRatio">0.8300653594771242</prop>
<tuv xml:lang="en">
<seg>pertussis (whooping cough) can be particularly serious in infants, causing coughing spells that may recur for up to two months.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kwalunkwe persuna li mhijiex imlaqqma bil-vaċċin tal-pertussis, jew li l-istatus tat-tilqim tagħha mhuwiex aġġornat, tinsab f'riskju li taqbadha l-marda.</seg>
</tuv>
</tu>
<tu tuid="462">
<prop type="lengthRatio">0.625</prop>
<tuv xml:lang="en">
<seg>How can HPV be prevented?</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kif tista' tiġi pprevenuta l-influwenza?</seg>
</tuv>
</tu>
<tu tuid="463">
<prop type="lengthRatio">2.0757575757575757</prop>
<tuv xml:lang="en">
<seg>For example, due to an increasing number of measles cases among teenagers and young adults, catch-up programmes exist in a number of EU/EEA countries for people who may have missed the measles vaccination when they were younger or are too old to have received it as a child.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dan jgħin biex tiġi eskluża l-possibbiltà li kienet koinċidenza jew li ġiet ikkawżata minn fatturi mhux relatati mal-vaċċin innifsu.</seg>
</tuv>
</tu>
<tu tuid="464">
<prop type="lengthRatio">0.9381443298969072</prop>
<tuv xml:lang="en">
<seg>Mild reactions such as fever, redness or swelling at the injection site have been reported.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Jekk in-nies jieqfu jitlaqqmu, ħafna minn dan il-mard u t-tifqigħat relatati jistgħu jirritornaw.</seg>
</tuv>
</tu>
<tu tuid="465">
<prop type="lengthRatio">2.141304347826087</prop>
<tuv xml:lang="en">
<seg>A variety of measures are employed to avoid the further spread of measles, such as quarantine from school or work for both the ill person and those close contacts with uncertain vaccination status.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Informazzjoni dwar liema pajjiżi għandhom tilqim obbligatorju tinsab fl-Aġenda tal-Vaċċini .</seg>
</tuv>
</tu>
<tu tuid="466">
<prop type="lengthRatio">1.1216216216216217</prop>
<tuv xml:lang="en">
<seg>Pertussis is a highly infectious bacterial disease involving the lungs and airways.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Dawn sempliċiment jikkunsidraw ċirkostanzi u sistemi tas-saħħa differenti.</seg>
</tuv>
</tu>
<tu tuid="467">
<prop type="lengthRatio">1.6506024096385543</prop>
<tuv xml:lang="en">
<seg>Most national vaccination programmes in the EU/EEA include vaccines for up to twenty diseases which are given to people at specific ages.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Kull pajjiż tal-UE/taż-ŻEE jimplimenta l-programm ta' immunizzazzjoni tiegħu stess.</seg>
</tuv>
</tu>
<tu tuid="468">
<prop type="lengthRatio">1.2962962962962963</prop>
<tuv xml:lang="en">
<seg>Vaccination schedules in the EU/EEA</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Sitwazzjoni tal-ħosba fl-UE</seg>
</tuv>
</tu>
<tu tuid="469">
<prop type="lengthRatio">1.0</prop>
<tuv xml:lang="en">
<seg>how it is manufactured.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>kif tingħata t-tilqima;</seg>
</tuv>
</tu>
<tu tuid="470">
<prop type="lengthRatio">0.9583333333333334</prop>
<tuv xml:lang="en">
<seg>time since vaccination;</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Xorta jistgħu jirkupraw.</seg>
</tuv>
</tu>
<tu tuid="471">
<prop type="lengthRatio">1.6304347826086956</prop>
<tuv xml:lang="en">
<seg>small white spots may also appear on the gums and the inside of the cheeks.</seg>
</tuv>
<tuv xml:lang="mt">
<seg>Illum il-ġurnata, hemm tilqim għal ħafna mard.</seg>
</tuv>
</tu>
<tu tuid="472">
<prop type="lengthRatio">1.2391304347826086</prop>
<tuv xml:lang="en">
<seg>This section provides links to the websites of other health organisations both at national and international level</seg>
</tuv>
<tuv xml:lang="mt">
<seg>It-tilqim jipprevjeni lin-nies milli jkollhom is-sintomi tal-marda, li jistgħu jkunu severi.</seg>
</tuv>
</tu>
</body>
</tmx>